Evaporable alkaloid compositions and methods of use thereof
Patent Information
- Application Number
- CN202380019269.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-01-18
- Filing Date
- 2023-07-28
- Publication Date
- 2024-11-19
AI Technical Summary
迄今为止,行业内尚未做到这一点,数据也证明了没有戒除
[0418]All structural, chemical, and functional equivalents known to those of ordinary skill in the art to the elements in the various embodiments described above are expressly incorporated by reference and are included in the present claims. Furthermore, the claims do not necessarily require that the instrument or parts of the instrument, or methods of using the instrument, solve every problem addressed by the present disclosure. Furthermore, no element, component or method step in the present disclosure is intended to be disclosed to the public, whether or not that element, component or method step is explicitly recited in the claims. Unless expressly recited using the phrase "means," no claim element may invoke Section 112(f) of Title 35, United States Code. As used herein, the terms "include," "comprises," or any other variation thereof are intended to cover a non-exclusive inclusion, e.g., chemicals, chemical compositions, processes, methods, articles, or equipment that include a range of elements and not just These elements are included and may also include other elements not expressly listed or inherent to the chemical, chemical composition, process, method, article or equipment.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_11
Abstract
Description
Inventors: CHARLOTTE L.OWEN; RICHARD AVILA JR.; GEOFF W.HABICHT Assignee: RediMed Natural Co., Ltd. CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to and the benefit of U.S. Provisional Patent Application Serial No. 63 / 439,650, filed on January 18, 2023, entitled “Vaping Liquid With Analogs For Vaping Devices,” the disclosure of which is incorporated herein by reference in its entirety for all purposes. Field of the Invention
[0002] The present disclosure generally relates to vaporizable inhalable compositions comprising physiologically active substances and sensory active substances, and more particularly to vaporizable compositions comprising one or more substituted pyridine compounds, or salts thereof, or mixed salts thereof. Background Art
[0003] It is well known that smokers can gain health benefits from quitting smoking, and overall, most adult smokers in the United States express a desire to quit. Depending on the composition of the vaporizable liquid, electronic nicotine delivery systems (ENDS) should, at least in principle, provide a viable smoking cessation aid for smoking. However, various studies have shown that users who self-administer nicotine using electronic devices are less likely to actually quit smoking. For example, see B. Kaplan et al., “Effectiveness of ENDS, NRT and Medication for Smoking Cessation Among Cigarette-Only Users,” Tob Control 2023;32:302-307 and R. El-Dib et al., “Electronic Nicotine Delivery Systems and / or Electronic Non-Nicotine Delivery Systems for Tobacco Smoking Cessation or Reduction: A Systematic Review and Meta-Analysis,” BMJ Open 2017;7:e012680.
[0004] Completely replacing actual tobacco smoking with electronically delivered vapor requires compliance, just as a patient complies with a medication prescription. For smokers, compliance with electronic devices depends on the sensory effects delivered electronically from the vaporizable composition being the same, or at least nearly the same, as inhaling tobacco smoke from a burning cigarette. To date, this has not been achieved within the industry, and data demonstrates that there is no quitting.
[0005] Therefore, there is a need for new vaporizable compositions that, when vaporized by an electronic device and inhaled, can provide an acceptable personal experience to former tobacco smokers. Summary of the invention
[0006] It has now surprisingly been found that vaporizable compositions can be optimized to provide a balance between the senses upon vaporization and inhalation, thereby simulating as closely as possible the sensory experience that an individual has when smoking a traditional tobacco product.
[0007] According to the present disclosure, novel vaporizable alkaloid compositions and compounding methods are provided.In general, the compositions herein optimize compliance with smoking cessation programs by providing smokers with a viable and complete tobacco substitute.
[0008] In various embodiments, the vaporizable alkaloid composition herein comprises at least one substituted pyridine compound, or a salt thereof, or a mixed salt thereof; at least one chemesy stimulant; at least one solvent; and optionally, at least one flavoring agent, wherein the vaporizable alkaloid composition is completely free of nicotine.
[0009] In various embodiments, the vaporizable alkaloid composition comprises:
[0010] at least one substituted pyridine compound of formula (I) or a salt or mixed salt thereof;
[0011]
[0012] Where R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl, provided that if R 5 is CH3, then R 1 , R 2 , R 3 and R 4 Cannot be all H;
[0013] at least one chemosensory stimulant;
[0014] at least one solvent; and
[0015] Optionally, at least one flavoring agent,
[0016] Wherein, the vaporizable alkaloid composition is completely free of (R) or (S) nicotine.
[0017] In various embodiments, R 5 is CH3, and R 1 , R 2 , R 3 and R 4 At least one of them is not H.
[0018] In various embodiments, R 5 Yes -(CH2)n-NR 6 R 7 , wherein n is an integer from 1 to 10, and R 6 and R 7 is independently selected from: H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl and substituted alkenyl, or R 6 and R 7 Together with the nitrogen atom to which it is bonded, it forms a 3-8 membered optionally substituted heterocyclic ring.
[0019] In various embodiments, R 5 is H, and R 1 , R 2 , R 3 and R 4 At least one of them is -(CH2)n-NR 6 R 7 , wherein n is an integer from 1 to 10, and R 6 and R 7 is independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl and substituted alkenyl, or R 6 and R 7 Together with the nitrogen atom to which they are bound, they form a 3-8 membered optionally substituted heterocyclic ring.
[0020] In various embodiments, the substituted pyridine compound or its salt or its mixed salt is selected from: (R) or (S)-3-(pyrrolidin-2-yl)pyridine, (R) or (S)-2-methyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-4-methyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-3-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2,6-dimethyl-3-(1-methylpyrrolidin-2-yl)pyridine, -(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2,4-dimethyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2,3-dimethyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2,4-dimethyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2,5-dimethyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-3,4-dimethyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)- 1-(2-aminoethyl)-2-(3-pyridyl)pyrrolidine, (R) or (S)-1-(3-aminopropyl)-2-(3-pyridyl)pyrrolidine, (R) or (S)-1-(4-aminobutyl)-2-(3-pyridyl)pyrrolidine, (R) or (S)-1-(5-aminopentyl)-2-(3-pyridyl)pyrrolidine, (R) or (S)-1-(2-dimethylaminoethyl)-2-(3-pyridyl)pyrrolidine, (R) or (S)-1-(3-dimethylaminopropyl)-2-(3-pyridyl)pyrrolidine, (R) or (S) )-1-(4-dimethylaminobutyl)-2-(3-pyridyl)pyrrolidine, (R) or (S)-3-(2-(6-methylpyridin-3-yl)pyrrolidin-1-yl)propionitrile, (R) or (S)-4-(2-(6-methylpyridin-3-yl)pyrrolidin-1-yl)butyronitrile, (R) or (S)-1-(3-aminopropyl)-2-(6-methyl-3-pyridyl)pyrrolidine, (R) or (S)-1-[3-(N,N-dimethylamino)propyl]-2-(6-methyl-3-pyridyl)pyrrolidine, (R) or (S)-1-(N,N-diethyl-3-aminopropyl-2-(3-pyridyl)pyrrolidine, (R) or (S)-3-(1-(2-(pyrrolidin-1-yl)ethyl)pyrrolidin-2-yl)pyridine, (R) or (S)-3-(1-(2-(piperidin-1-yl)ethyl)pyrrolidin-2-yl)pyridine, (R) or (S)-4-(2-(2-(pyridin-3-yl)pyrrolidone) (R) or (S)-3-(1-(3-(pyrrolidin-1-yl)propyl)pyrrolidin-2-yl)pyridine, (R) or (S)-3-(1-(3-(piperidin-1-yl)propyl)pyrrolidin-2-yl)pyridine and (R) or (S)-4-(3-(2-(pyridin-3-yl)pyrrolidin-1-yl)propyl)morpholine.
[0021] In various embodiments, the substituted pyridine compound or a salt thereof or a mixed salt thereof is (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine.
[0022] In various embodiments, the substituted pyridine compound or its salt or its mixed salt is selected from (2S)-1-methyl-2-(6-methylpyridin-3-yl)pyrrolidin-1-ium acetate, (2S)-1-methyl-2-(-6-methylpyridin-3-yl)pyrrolidin-1-ium citrate or a mixture thereof.
[0023] In various embodiments, the chemosensory stimulant is selected from the group consisting of oleocanthal, 4-hydroxy-2-nonenal, 4-oxo-2-nonenal, allicin, allyl isothiocyanate, icilin, polygodial, cinnamaldehyde, trans-p-methoxycinnamaldehyde, methyl syringate, 2-chlorobenzylidenemalononitrile, 1-chloroacetophenone, ethyl bromoacetate, 4-hydroxyhexenal, toluene diisocyanate , p-benzoquinone, methyl paraben, flufenamic acid, niflumic acid, mefenamic acid, diclofenac, hydroxy-α-sanshool, paradol, linalool, carvacrol, eugenol, thymol, vanillin, methyl eugenol, 2,6-dimethylphenol, 2,5-dimethylphenol, 3,4-dimethylphenol, 2,6-diisopropylphenol, caffeine, farnesylthiosalicylic acid acid, 4-allylanisole, curcumin, niacin, camphor, olvanil, arvanil, anandamide, baicalein, baicalin, wogonin, norwogonin, oroxylin A, beta-sitosterol, and mixtures thereof.
[0024] In various embodiments, at least one substituted pyridine compound of formula (I) or a salt thereof or a mixed salt thereof consists of a mixture of (S)-2-methyl-3-(1-methylpyrrolidin-2-yl)pyridine free base and a mixed salt of (2S)-1-methyl-2-(6-methylpyridin-3-yl)pyrrolidin-1-ium citrate / acetate.
[0025] In various embodiments, the chemesy stimulant is a spice additive that exhibits a pungency of about 1,000 to about 20,000,000 Scoville Heat Units (SHU).
[0026] In various embodiments, the spice additive is selected from the group consisting of capsaicin, dihydrocapsaicin, norcapsaicin, nordihydrocapsaicin, homocapsaicin, homodihydrocapsaicin, gingerol, piperine, shogaol, isopiperine, chavicine, isochavicine, 2-piperamine, piperanine (4,5-dihydropiperine), piperonamide, 4-pipericide, piperyline, piperlonguminine, piperettine, piperdardine (6,7-dihydropiperettine), 5-sarmentodine, 6-sarmentine, 7-trichostachine, and mixtures thereof.
[0027] In various embodiments, the spice additive is capsaicin or a mixture of capsaicinoids.
[0028] In various embodiments, the solvent is selected from propylene glycol, water, ethanol, glycerol, and mixtures thereof.
[0029] In various embodiments, the vaporizable alkaloid composition further comprises an organic acid selected from the group consisting of formic acid, acetic acid, trifluoroacetic acid, aspartic acid, butanoic acid, butyric acid, 2-methylbutyric acid, 3-methylbutyric acid, benzoic acid, caprylic acid, citric acid, crotonic acid, ethylenediaminetetraacetic acid, fumaric acid, gluconic acid, glutamic acid, glyceric acid, glycolic acid, lactic acid, lauric acid, levulinic acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, oxalic acid, phenylacetic acid, phthalic acid, picric acid, propionic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, tartronic acid, valeric acid, and mixtures thereof.
[0030] In various embodiments, the organic acid is selected from the group consisting of citric acid, acetic acid, benzoic acid, tartaric acid, lactic acid, salicylic acid, malic acid, levulinic acid, and mixtures thereof.
[0031] In various embodiments, the molar ratio of total substituted pyridine compounds to total organic acid is from about 25:1 to about 75:1.
[0032] In various embodiments, the vaporizable alkaloid composition comprises:
[0033] From about 1% to about 80% by weight of a substituted pyridine compound of formula (I) or a salt or mixed salt thereof:
[0034]
[0035] Where R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl, provided that if R 5 is CH3, then R 1 , R 2 , R 3 and R 4 Cannot be all H;
[0036] from about 0.05 wt % to about 1.5 wt % total of at least one organic acid;
[0037] from about 0.0001% to about 0.50% by weight of a spice additive, the spice additive having a pungency of from about 1,000 to about 20,000,000 Scoville Heat Units (SHU); and
[0038] Residual solvent,
[0039] wherein the weight percentage is based on the total weight of the vaporizable alkaloid composition; and the molar ratio of the moles of the substituted pyridine compound to the total moles of the organic acid is from about 25:1 to about 75:1.
[0040] In various embodiments, the substituted pyridine compound is (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine.
[0041] In various embodiments, the molar ratio of the moles of (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine to the total moles of the organic acid is about 50:1.
[0042] In various embodiments, the (w / v) concentration of (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine in the vaporizable alkaloid composition is from about 1 mg / mL to about 1,000 mg / mL.
[0043] In various embodiments, the (w / v) concentration of (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine in the vaporizable alkaloid composition is about 100 mg / mL.
[0044] In various embodiments, the at least one organic acid consists of a mixture of citric acid and acetic acid.
[0045] In various embodiments, the spice additive includes capsaicin.
[0046] In various embodiments, the solvent is selected from the group consisting of propylene glycol, glycerol, ethanol, and mixtures thereof.
[0047] In various embodiments, a method of preparing a vaporizable alkaloid composition comprises:
[0048] preparing a first premix comprising at least one organic acid and a chemosensory stimulant dissolved in a suitable solvent or solvent mixture;
[0049] A second premix is prepared, comprising at least one substituted pyridine compound having the structure of formula (I) dissolved in a suitable solvent or solvent mixture:
[0050] or its salt or mixed salt thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl, provided that if R 5 is CH3, then R 1 , R2 , R 3 and R 4 It can’t all be H;
[0051] combining the first premix and the second premix; and
[0052] The resulting mixture is optionally heated until the resulting mixture becomes optically clear, thereby producing a vaporizable alkaloid composition.
[0053] In various embodiments, the first premix comprises a mixture of capsaicin or capsaicinoids, acetic acid, and citric acid dissolved in a mixture of propylene glycol and ethanol, and the second premix comprises (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine dissolved in glycerol.
[0054] In various embodiments, a method of promoting smoking cessation in an individual who desires to quit smoking comprises:
[0055] During the determined smoking cessation period, the individual is administered a series of vaporizable alkaloid compositions for inhalation by the individual via vaporization, each of the series of vaporizable alkaloid compositions comprising at least one substituted pyridine compound having formula (I) or a salt or mixed salt thereof:
[0056] Where R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl, provided that if R 5 is CH3, then R 1 , R 2 , R 3 and R 4 Cannot be all H;
[0057] wherein a series of vaporizable alkaloid compositions each comprises a decreasing (w / v) amount of said substituted pyridine compound or a salt or mixed salt thereof; and
[0058] Wherein, starting from a composition using the highest content (w / v) of the substituted pyridine compound or its salt or its mixed salt, and ending with a determined abstinence period starting from a composition using the lowest content (w / v) of the substituted pyridine compound or its salt or its mixed salt, the individual inhales by atomizing each composition in a series of compositions, so that at the end of the determined abstinence period, the individual quits smoking.
[0059] In various embodiments, each vaporizable alkaloid composition in the series of vaporizable alkaloid compositions comprises (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine or a salt or mixed salts thereof.
[0060] In various embodiments, the vaporizable alkaloid composition in the series of vaporizable alkaloid compositions having the highest level (w / v) of said substituted pyridine compound or salt or mixed salts thereof comprises about 100 mg / mL of (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine.
[0061] In various embodiments, the vaporizable alkaloid composition in the range of vaporizable alkaloid compositions having low levels (w / v) of said substituted pyridine compound or salt or mixed salts thereof comprises no more than about 1 mg / mL of (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine.
[0062] In various embodiments, the determined abstinence period is part of a smoking cessation program, the smoking cessation program further comprising dispensing a series of vaporizable alkaloid compositions to an individual who wishes to quit smoking during the determined abstinence period.
[0063] In various embodiments, an alkaloid dispensing bag suitable for releasing an alkaloid therefrom into the oral cavity of a subject comprises:
[0064] A saliva-permeable nonwoven fabric defining an outer shell containing an alkaloid composition filled therein, the alkaloid composition comprising:
[0065] At least one substituted pyridine compound of formula (I) or a salt or mixed salt thereof:
[0066] Where R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl, provided that if R 5 is CH3, then R 1 , R 2 , R 3 and R 4 cannot all be H; and
[0067] carrier,
[0068] The alkaloid dispensing bag is completely free of (R) or (S) nicotine.
[0069] In various embodiments, the alkaloid composition comprises a mixture of the substituted pyridine compound of formula (I) and the carrier.
[0070] In various embodiments, the carrier comprises microcrystalline cellulose.
[0071] In various embodiments, the alkaloid composition further comprises a solvent, wherein the alkaloid composition consists of a liquid composition adsorbed onto the carrier.
[0072] In various embodiments, the alkaloid composition further comprises a chemesthesia stimulant. In various embodiments, the chemesthesia stimulant comprises a spice having a pungency of about 1,000 to about 20,000,000 Scoville Heat Units (SHU).
[0073] In various embodiments, an alkaloid dispensing bag suitable for releasing an alkaloid therefrom into the oral cavity of an individual comprises: a saliva permeable nonwoven fabric defining an outer shell containing an alkaloid composition filled therein, the alkaloid composition comprising a vaporizable alkaloid composition further comprising at least one substituted pyridine compound of formula (I) or a salt or mixed salt thereof:
[0074] Where R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl, provided that if R 5 is CH3, then R 1 , R 2 , R 3 and R 4 cannot be all H; at least one chemosensory stimulant; at least one solvent; and optionally, at least one flavoring agent, wherein the vaporizable alkaloid composition is completely free of (R) or (S) nicotine; and wherein the vaporizable alkaloid composition is adsorbed on a carrier.
[0075] In various embodiments, the vaporizable alkaloid composition comprises (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, citric acid, and acetic acid.
[0076] In various embodiments, the carrier comprises microcrystalline cellulose.
[0077] In various embodiments, the chemesy stimulant comprises capsaicin or a mixture of capsaicinoids.
[0078] In various embodiments, the solvent is selected from propylene glycol, water, ethanol, glycerol, and mixtures thereof. Detailed description
[0079] The detailed description of the exemplary embodiments refers to the accompanying drawings, which illustrate the exemplary embodiments and their best modes in a diagrammatic manner. Although the description of these exemplary embodiments is detailed enough to enable those skilled in the art to implement the present invention, it should be understood that other embodiments may also be implemented and that logical, chemical and mechanical changes may be made without departing from the spirit and scope of the present invention. Therefore, the detailed description is provided for illustrative purposes only, not for limiting purposes. For example, unless otherwise specified, the steps recorded in any method or process description may be performed in any order and are not necessarily limited to the order presented. In addition, any reference to the singular includes plural embodiments, and any reference to more than one component or step may include singular embodiments or steps. In addition, any reference to attachment, fixing, connection or the like may include permanent, removable, temporary, partial, complete and / or any other possible attachment method. In addition, any reference to contactless (or similar phrases) may also include reduced contact or minimal contact.
[0080] In various embodiments of the present disclosure, novel vaporizable alkaloid compositions are disclosed. Compositions are optimized herein to provide a balance between nose, throat, and head senses during vaporization and inhalation, thereby simulating as closely as possible the sensory experience of an individual when smoking a traditional tobacco product. In general, optimizing the compositions herein helps to comply with a smoking cessation program. In various embodiments herein, a feasible complete alternative to smoking is provided for tobacco smokers.
[0081] In various embodiments, the vaporizable alkaloid composition herein comprises:
[0082] at least one substituted pyridine compound or a salt or mixed salt thereof;
[0083] at least one chemosensory stimulant;
[0084] at least one solvent; and
[0085] Optionally, at least one flavoring agent, wherein the vaporizable alkaloid composition is completely free of nicotine.
[0086] In some examples, the compositions provided herein can be diluted with an appropriate solvent or solvent mixture (such as vegetable glycerin and / or propylene glycol) before evaporation and inhalation, for example, by a third-party manufacturer or an end user of a refillable electronic device to provide a customized inhalable composition with less substituted pyridine compounds and spice additives than the initial composition. In a preferred example, the third party will design and implement a smoking cessation plan for an individual and provide a vaping liquid (vaping liquid) with a gradually reduced content of substituted pyridine compounds and spice additives during the implementation of the plan. In this way, consumers can comply with the smoking cessation plan and use a vaping liquid with less and less substituted pyridine compounds and spice additives over time until the user substantially inhales the vaping solvent (without other discernible substances except possible flavoring agents).
[0087] Definitions and Explanations:
[0088] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art of chemistry and medicinal chemistry associated with the present disclosure. Although any methods and materials similar or equivalent to the methods and materials described herein can be used in the practice or testing of the disclosed subject matter, preferred methods and materials are described herein. According to the usual practice of organic chemistry, chemical structures with chiral centers are either displayed with wavy bonds thereon, or are not displayed with wedge-shaped bonds or dashed bonds in three dimensions, or are not marked with (R) or (S) near the chiral center or in the corresponding structure name, and are considered to represent two enantiomers. Similarly, chemical structures assuming multiple chiral centers that are not presented in three dimensions or labeled as having a specific chirality include all possible stereoisomers. The compounds of the present disclosure include any physicochemical or stereochemical forms they may have, for example, isomers, prodrugs, active metabolites, tautomers, stereoisomers, positional isomers, solvated forms, salts, and polymorphs. Amorphous forms lack distinguishable lattices and therefore lack an ordered arrangement of structural units. Many alkaloids have an amorphous form, a crystalline form, or a mixture thereof. In addition to crystallographic methods to determine the degree and type of crystallinity, methods of generating such chemical forms are known to those skilled in the art.
[0089] The alkaloids included in the compositions of the present disclosure can be protonated by the acid also present in the compositions, so that at least part or even all of the compositions are present in the form of salts in various compositions. Alkaloid salts include any salt derived from an inorganic acid or an organic acid (preferably an organic acid) or a mixture thereof. Examples of inorganic salts include, but are not limited to, salts of hydrobromic acid, hydrochloric acid, nitric acid, phosphoric acid, and sulfuric acid. Examples of organic acid salts include, for example, salts of formic acid, acetic acid, trifluoroacetic acid, aspartic acid, butanoic acid, butyric acid, 2-methylbutyric acid, 3-methylbutyric acid, benzoic acid, caprylic acid, citric acid, crotonic acid, ethylenediaminetetraacetic acid (EDTA), fumaric acid, gluconic acid, glutamic acid, glyceric acid, glycolic acid, lactic acid, lauric acid, levulinic acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, oxalic acid, phenylacetic acid, phthalic acid, picric acid, propionic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, tartronic acid, valeric acid, and any combination thereof, or any other such acid currently known or not yet discovered or synthesized. Such alkaloid salts can be prepared by reacting a non-alkaloid base compound with a suitable acid or a mixture of acids in a manner known to those skilled in the art. When a mixed acid is reacted with an alkaloid disclosed herein to prepare an alkaloid salt, no attempt is made to quantify the mole percentage of each individual alkaloid salt produced, but rather the resulting alkaloid salt is referred to as a "mixed salt."
[0090] As used herein, the term "alkyl" refers to a linear or branched monovalent saturated hydrocarbon substituent, which is optionally substituted with one or more functional groups at any position on or within the substituent. Unless otherwise specified, an alkyl group may contain any number of carbon atoms, e.g., C1-C 24 、C1-C 18 、C1-C 10 , C1-C8 or C1-C6. Examples of alkyl substituents include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl, octadecyl, dodecyl, etc. The alkyl substituents herein may be substituted, i.e., have one or more substituents attached to the alkyl or incorporated into the alkyl chain. The substituents in the alkyl substituent chain may include ether, thioether, amino or imine connections, such as -O-, -S-, -N(R')- or -N=, or some other intermediate heteroatoms. Examples of substituents on alkyl substituents include, but are not limited to: -CN, -N3, -NH2, -NHR', -N(R')2, -NO2, -NH-NH2, -NH-NHR', -NH-NR'2, -halogen, -SH, -SR', -S(=O)R', -SO2R', -OPO3 2- 、-PO32- , -OH, -OR', -C(=O)R', -OC(=O)R', -CO2R', -NHC(=O)R', -NR'C(=O)R', -C(=O)NHR', -C(=O)NR'2, alkyl, alkenyl, cycloalkyl, heterocyclyl and aryl, wherein each R'above is independently selected from hydrogen-H and alkyl moieties, including, for example, C 1-6 Alkyl (e.g., -CH3, -C2H5, -isopropyl, -tert-butyl, etc.), C 1-6 Alkoxy (e.g., -OCH3, -OC2H5), halogenated C 1-6 Alkyl (e.g., -CF3, -CHF2, -CH2F) and halogenated C 1-6 Alkoxy (eg, -OCF3, -OC2F5). In various instances, two R' substituents in any of these functional groups can form a ring structure.
[0091] As used herein, the term "cycloalkyl" includes any 3-, 4-, 5-, 6-, 7- or 8-membered, saturated or unsaturated, non-aromatic carbocyclic ring, which is optionally substituted by one or more functional groups at any position on the ring substituent. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopentadienyl, 2-cyclopentadienyl or 5-cyclopentadienyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl or 4-cyclohexenyl, 1-(1,3-cyclohexadienyl), 2-(1,3-cyclohexadienyl) or 5-(1,3-cyclohexadienyl), 1-(1,4-cyclohexadienyl) or 3-(1,4-cyclohexadienyl), cycloheptyl, 1-cycloheptenyl, 3-cycloheptenyl, 4-cycloheptenyl or 5-cycloheptenyl, cyclooctane, etc. Examples of substituents on cycloalkyl substituents include, but are not limited to: -CN, -N3, -NH2, -NHR', -N(R')2, -NO2, -NH-NH2, -NH-NHR', -NH-NR'2, -halogen, -SH, -SR', -S(=O)R', -SO2R', -OPO3 2- 、-PO3 2- , -OH, -OR', -C(=O)R', -OC(=O)R', -CO2R', -NHC(=O)R', -NR'C(=O)R', -C(=O)NHR', -C(=O)NR'2, alkyl, alkenyl, cycloalkyl, heterocyclyl and aryl, wherein each R'above is independently selected from -H and alkyl moieties, including, for example, C 1-6 Alkyl (e.g., -CH3, -C2H5, -isopropyl, -tert-butyl, etc.), C 1-6 Alkoxy (e.g., -OCH3, -OC2H5), halogenated C 1-6 Alkyl (e.g., -CF3, -CHF2, -CH2F) and halogenated C1-6 Alkoxy (e.g., -OCF3, -OC2F5).
[0092] As used herein, the term "alkenyl" refers to a linear or branched monovalent or divalent unsaturated hydrocarbon substituent, which is optionally substituted with one or more functional groups at any position on or within the substituent. 2 If carbon is part of the molecule bearing the alkenyl substituent, the alkenyl substituent may be considered divalent. An illustrative example is methylenecyclohexane, which may be considered cyclohexane substituted with a methylene group (i.e., a divalent alkenyl substituent, =CH2). Unless otherwise specified, an alkenyl group may contain any number of carbon atoms, e.g., C1-C 24 、C1-C 18 、C1-C 10 , C1-C8 or C1-C6, and any degree of unsaturation. Examples of alkenyl substituents include, but are not limited to, methylene / methylene (=CH2), ethylene / vinyl (-CH=CH2 or =CH-CH3), propylene / propylene (-CH2-CH=CH2, cis or trans-CH=CH-CH3, =C(CH3)2 or cis or trans=CH-CH2CH3), etc. The alkenyl substituents herein may be substituted, i.e., have one or more substituents attached to the alkenyl or incorporated into the alkenyl chain. The substituents in the alkenyl substituents may include ether, thioether, amino or imine connections, such as -O-, -S-, -N(R')- or -N=, or some other intermediate heteroatoms. Examples of substituents on alkenyl substituents include, but are not limited to: -CN, -N3, -NH2, -NHR', -N(R')2, -NO2, -NH-NH2, -NH-NHR', -NH-NR'2, -halogen, -SH, -SR', -S(=O)R', -SO2R', -OPO3 2- 、-PO3 2- , -OH, -OR', -C(=O)R', -OC(=O)R', -CO2R', -NHC(=O)R', -NR'C(=O)R', -C(=O)NHR', -C(=O)NR'2, alkyl, alkenyl, cycloalkyl, heterocyclyl and aryl, wherein each R'above is independently selected from an alkyl moiety, including, for example, C 1-6 Alkyl (e.g., -CH3, -C2H5, -isopropyl, -tert-butyl, etc.), C 1-6 Alkoxy (e.g., -OCH3, -OC2H5), halogenated C 1-6 Alkyl (e.g., -CF3, -CHF2, -CH2F) and halogenated C 1-6 Alkoxy (eg, -OCF3, -OC2F5). In various instances, two R' substituents in any of these functional groups can form a ring structure.
[0093] As used herein, unless otherwise specified, the term "propylene glycol" or more simply "PG" refers to propane-1,2-diol (α-propylene glycol), rather than the 1,3-diol isomer. In addition, unless otherwise specified, propylene glycol as used herein comprises a racemic mixture of isomers and is typically produced on a global industrial scale by hydrolysis of propylene oxide. PG is generally a recognized ingredient in vaporizable compositions that is responsible for the white vapor cloud observed when vaping.
[0094] As used herein, the term "vegetable glycerin" or more simply "VG" has its ordinary meaning in organic chemistry and food science, namely, HOCH2-CH(OH)-CH2OH, a triglyceride derived from plant sources.
[0095] As used herein, the term "inhalable" refers to a feature of the vaporizable alkaloid composition according to the present disclosure, i.e., the composition is suitable for inhalation by a user. The inhalable alkaloid composition disclosed herein is vaporizable and thus suitable for use in an electronic cigarette device, meaning that it can be vaporized by a heating element within such an electronic device, thereby allowing the user to inhale in the so-called "vaping" practice. In other words, the vaporizable alkaloid composition herein is an inhalable composition. Unless otherwise specified, the phrase "inhalable composition" or "inhalable compositions" refers to a vaporizable alkaloid composition according to the present disclosure.
[0096] As used herein, the term "electronic cigarette" or "ENDS" (electronic nicotine delivery system) generally refers to any electronic device capable of vaporizing a liquid composition into a vapor that can be inhaled by an individual using the device. For the purpose of not limiting, "electronic cigarette" herein refers to any design, such as a cigar, an vape pen, or any other refillable or disposable electronic device, that has a reservoir containing a vaporizable liquid therein and has the ability to vaporize the vaporizable liquid. For simplicity, the term "electronic device" may be used to refer to any and all refillable and disposable electronic cigarette instruments.
[0097] As used herein, the term "throat hit" refers to the sensory effect felt in the back of the throat by an individual inhaling vapor, such as vapor obtained from a burning cigarette or vapor generated from an electronic device (such as an electronic cigarette that vaporizes a liquid component). Throat hit is an irritating "bite" sensation experienced in the back of the throat that, prior to the development of electronic cigarettes, was not only experienced by smokers but also expected and enjoyed by smokers. Although throat hit is subjective rather than objective, it can be quantified through the use of a sensory panel, for example, in which participants in the panel rank the perceived throat hit on a scale of 1-10, or by comparing the throat hit of electronic cigarette products and / or electronic cigarette products relative to traditional cigarettes. In some examples, in the comparison, throat hit can be quantified as less than, equal to, or greater than the throat hit experienced by a particular cigarette. An exemplary cigarette for standardizing throat hit (e.g., in a sensory panel in which participants rank throat hit) is Filter cigarettes GoldPack 100's, available from Phillips IGA. As explained herein, throat hit can be achieved in an individual generally by including a chemesyoriental stimulant in the vaporizable alkaloid compositions of the present disclosure, and in particular by using a flavor additive as a chemesyoriental stimulant.
[0098] As used herein, the term "vaping" refers to the act of using an electronic cigarette or other ENDS device to inhale a vapor electronically generated by evaporation of a liquid composition. Electronic cigarettes are considered to be similar to the endeavor of smoking tobacco products, recognizing that electronic cigarettes and vaping are not limited to nicotine. Vaping can include personal inhalation of nicotine analogs, other physiologically active substances, flavors, etc.
[0099] As used herein, the term "vape juice" or "e-juice" refers to a liquid composition that can be vaporized in an electronic cigarette or other ENDS device to produce a vapor that can be inhaled by an individual performing a puff. In various embodiments herein, a vape juice composition is described, which in some instances includes a vaporizable alkaloid composition and a dilution thereof.
[0100] The term "cloud," as used herein, refers to the white vapor that is visible when a smoking liquid is inhaled and exhaled from an e-cigarette or other ENDS device. As discussed herein, cloud is an important characteristic for successful smoking of a smoking liquid because it is a characteristic that smokers seek. Although the appearance of cloud is subjective rather than objective, it can be quantified through the use of a sensory panel, for example, in which participants in the panel rank the appearance of the cloud on a scale of 1-10 when smoking an e-cigarette, or compare e-cigarette products and / or to the cloud seen in the air when smoking a traditional combusted cigarette. In some examples, in the comparison, the cloud can be quantified as less than, equal to, or greater than the cloud seen when smoking a particular cigarette. An exemplary cigarette for standardizing the appearance of cloud (e.g., in a sensory panel in which participants rank the appearance of cloud) is Filter cigarettes Gold Pack 100's, available from Phillips IGA.
[0101] As used herein, the term "dizziness" refers to the dizziness experienced by tobacco smokers and e-cigarette users who inhale products containing nicotine, nicotine analogs, THC, and other physiologically active substances. Smokers describe this sensory experience as a ringing sensation in their heads or a surge of adrenaline. It is believed that this sensory effect is caused by nicotine or other drugs in the blood and brain triggering the release of adrenaline, which causes blood vessels to tighten and the heart rate and blood pressure of people who inhale active substances to temporarily increase. This sensory experience is personal and varies between drug active substances and between individuals due to differences in physiological tolerance. Dizziness may occur within 10 seconds after inhaling nicotine and may last up to 10-30 minutes. However, as smokers or e-cigarette users continue to smoke or vape e-cigarettes, they become more tolerant and the dizziness that is often experienced becomes shorter over time. Although dizziness is subjective rather than objective, it can be quantified by using a sensory panel, for example, participants in the panel rank the perceived dizziness on a scale of 1-10, or compare e-cigarette products and / or e-cigarette products relative to the dizziness of traditional cigarettes. In some examples, the dizziness can be quantified as less than, equal to, or greater than the dizziness experienced by a particular cigarette in the comparison. An exemplary cigarette used to standardize the throat hit (e.g., in a sensory panel where participants rank the throat hit) is Filter cigarettes Gold Pack 100's, available from Phillips IGA.
[0102] As used herein, the term "chemical sensory irritant" has the common meaning in physiology and neuroscience, that is, a substance that can show sensory stimulation in an individual exposed to the substance. Depending on the individual and the irritant, the stimulation caused by the chemical sensory irritant during inhalation can be perceived in the nose, mouth, throat, esophagus and / or lungs. The sensory effect in the throat is referred to as "throat hit" in the definition of this article. Most of the research on chemical sensory stimulation is carried out in the context of environmental and occupational health and safety, involving indoor environmental irritants such as air pollutants and formaldehyde. For example, see "Inhalation Toxicology", 2nd edition, edited by H. Salem et al., Taylor & Francis Group (Taylor & Francis Group) (CRC), 2006. In addition to subjective measures of chemosensory irritation (e.g., panelists answering symptom questionnaires), various experimental techniques can be used to study irritation caused by chemicals, such as examination of functional changes, for example, changes in respiratory rate and pattern, nasal, bronchial and lung function parameters, nasal mucosal swelling, acoustic rhinography, blink rate, tear film stability, and chemosensory evoked potentials in humans and experimental animals (see SK Kjaergaar et al., "The Assessment of Irritation Using Clinical Methods and Questionnaires," American Industrial Hygiene Association, 62(6):711-6, November 2001).
[0103] Chemoreceptorial irritants for use in the vaporizable alkaloid compositions of the present disclosure include those compounds that are capable of causing physiological irritation to any of the nose, mouth, throat, esophagus, and lungs of an individual, wherein the physiological irritation is quantifiable. Examples of quantitative methods include, but are not limited to, measuring swelling of the nasal mucosa, peak airflow through the nose, acoustic rhinometry, and nasal stereometry for measuring the thickness of the anterior turbinate. Questionnaires can also be used to define a set of symptoms to describe a dose-response relationship in controlled exposure studies.
[0104] In various embodiments, the chemosensory stimulants used in the vaporizable alkaloid compositions herein are substances capable of activating chemosensory ion channels known as transient receptor potential channels or TRP channels, as explained, for example, by HJ Son et al., "Activation of chemosensory ion channels TRPA1 and TRPV1 by hydroalcoholic extract of Acanthopanax senticosus leaves," Biomol. Ther, (Seoul), November 2012; 20(6): 550-555. In addition to the subset of chemosensory stimulants defined below as "spice additives", many seemingly unrelated compounds are receptor agonists and are capable of activating one or more TRP channels (e.g., A1, V1, V2, V3, V4, V5 or V6, M1, M2, M3, M4, M5, M6, M7 or M8 ion channels, etc.), for example, oleocanthal, 4-hydroxy-2-nonenal, 4-oxo-2-nonenal, allicin, allyl isothiocyanate, gingerols (included in the spice subclass of stimulants), icilin, polygodial, cinnamaldehyde, trans-p-methoxycinnamaldehyde, methyl syringate, 2-chlorobenzylidenemalononitrile, 1-chloroacetophenone, ethyl bromoacetate, 4-hydroxy 6-Zingiol (included in the spice subset of irritants), 6-Zingiol (paradol), linalool, carvacrol, eugenol, thymol, vanillin, methyl eugenol, 2,6-dimethylphenol, 2,5-dimethylphenol, 3,4-dimethylphenol, 2,6-diisopropylphenol, caffeine, farnesylthiosalicylicacid, 4-allylanisole, curcumin, capsaicin (included in the spice subset of irritants), nicotinic acid, camphor, olvanil and arvanil. Although nicotine is a known TRPA1 activator, it is excluded from the chemosensory stimulants of the vaporizable alkaloid composition herein. See, for example, K. Talavera et al., "Nicotine activates the chemosensory cation channel TRPA1", Nature Neuroscience, 12, 1293-1299 (2009). One aspect of the present disclosure is to provide a vaporizable alkaloid composition that is significantly free of nicotine, so that it can be used as a substitute for smoking. An inventive aspect of the composition of the present invention is that the composition contains a chemosensory stimulant in place of nicotine to simulate the stimulating effect of tobacco smoke.
[0105] In addition, chemosensory stimulants that activate TRP ion channels and are therefore useful in the vaporizable alkaloid compositions herein include a variety of compounds naturally present in various plants, trees, shrubs, roots, flowers, fruits, seeds, and nuts. For example, J. Vriens et al. disclose such compounds in the book Herbal Compounds and Toxins Modulating TRP Channels (Neuropharmacology, March 2008; 6(1): 79-96). In various embodiments, in addition to the "spice additives" defined and discussed herein (including compounds such as capsaicinoids, gingerols and shogaols), other TRP channel activators may also be used herein and include, but are not limited to: resins from Euphorbia reinifera, eugenols from Euenia carophyllata and Ocimum gratissiumum, ginsenosides from Panax, gingerols and zingerones from gingerols heated or dehydrated or from seeds of Aframomum melgueta, evodia compounds from Evodia rutaecarpa, various unsaturated 1,4-dialdehyde sesquiterpenes isolated from Drymis winteri, such as polygonial, isopolygonal and drimanial, from Cinnamomum melgueta seeds. Other 1,4-dialdehyde terpenes from fragrans, such as cinnamaldehyde, cinnamosmolide, and cinnamolide, or valerianaldehyde from Warburgia plants. In vitro assays for measuring TRP ion channel activation can be found in the following articles: R. Lehmann et al., "Alternative in vitro assays to assess the potency of sensory irritant–Is one TRP channel enough?" Neurotoxicology, May 2017, 60:178-186; and JM Martinez et al., "Activation of TRPA1 by volatile organic chemicals leading to sensor yirritation," ALTEX 2019; 36(4):572-582.Of more importance for use herein are the phytochemicals present in Scutellaria baicalensis (most particularly the phytochemicals baicalein, baicalin, wogonin, norwogonin, oxyphyllin A and beta-sitosterol), Vitexagnus, Pterodon pubescens, Croton macrostachyus, Angelica epubescentis, Ephedra sinica, Amphilophium crucigerum, Bosewellia carterii, Commiphora myrrha, Echinophora platyloba, Nypa fruticans, Zingiber officiale (listed in the stimulant spice additive subset), Corydalis saxicola, Coptis chinensis, Ononis spinosa), Parkia platycephala, Piper nigrum (listed in the stimulant spice additive subset) and Cymbopogon citratus. Chemoreceptor stimulants for use herein can be evaluated first by in vitro non-animal sensory irritation assays, followed by consumer sensory panels to evaluate subtle physiological effects and determine dosage levels and user acceptance.
[0106] As used herein, the term "spice additive" refers to an organic substance that is capable of producing a throat hit or other similar "hot," "irritating," or other "burning" sensation at least in the back of the throat, and optionally in the mouth and lips, when the spice additive is in a vaporizable alkaloid composition that is vaporized and inhaled by an individual (e.g., a person smoking an e-cigarette). The spice additives herein form a subset of chemosensory stimulants and are known to activate one or more TRP ion channels. Since these groups of compounds may be structurally unrelated at first glance, "spice additives" herein can be specifically defined as organic substances having a spicy taste or "heat" ranging from about 1,000 to about 20,000,000 Scoville Heat Units (SHU). At the lower end of the Scoville scale, compounds used herein include, but are not limited to, gingerols (60,000 SHU), piperine (100,000 SHU), and gingerols (160,000 SHU). In a more preferred embodiment, the Scoville rating of the spice additive used in the vaporizable alkaloid composition herein is from about 100,000 to about 20,000,000 SHU, more preferably from about 10,000,000 to about 20,000,000 SHU, and will include all known capsaicinoids, such as capsaicin (16,000,000 SHU) and dihydrocapsaicin (15,000,000 SHU), as well as uncharacterized capsaicinoid compounds that may be isomers of known capsaicinoids. Although chemically unrelated to the capsaicinoids, compounds such as piperine (100,000 SHU) and shogaol (160,000 SHU) can be used in the composition of the present invention. Capsaicinoid spice additives used herein include, but are not limited to, capsaicin, dihydrocapsaicin, norcapsaicin, nordihydrocapsaicin, homocapsaicin, homodihydrocapsaicin, and mixtures thereof. Chemically pure or otherwise isolated capsaicinoids are not necessary for the vaporizable alkaloid compositions herein, as it is also convenient to prepare various compositions with extracts of spice additives. For example, capsaicinoids can be extracted from peppers or other peppers using room temperature or boiling ethanol (e.g., in a Soxhlet extractor). The resulting red ethanol solution can be used directly (referred to as "capsaicin liquid" or "liquid capsaicin") or evaporated to leave a thick, dark red, viscous capsaicinoid mixture (the red color is believed to come from beta-carotene).See, e.g., F. Martins et al., "Novel Approaches to Extraction Methods in Recovery of Capsaicin from Habanero Pepper (CNPH 15.192)", Pharmacogn. Mag. 2017 Jul; 13(Suppl 2): S375-S379 and Y. Zhu, "Multi-Dimensional Pungency and Sensory Profiles of Powder and Oil of Seven Chili Peppers Based On Descriptive Analysis and Scoville Heat Units", Food Chemistry, 411, June 15, 2023, article 135488.
[0107] As used herein, the term "liquid capsaicin" or "capsaicin liquid" refers to an ethanol extract or other solvent extract of the fruit obtained from a plant of the genus Capsicum (e.g., various peppers). Liquid capsaicin preferably used herein contains about 0.9% by weight of total capsaicin in ethanol and can be purchased from OliveNation, LLC, Avon, MA under the trade name Capsicum Flavor Extract.
[0108] It should be noted that the optional "flavoring agents" for the vaporizable alkaloid compositions herein are defined separately and are completely distinct from "chemesensory stimulants" and the subset of stimulants referred to herein as "spice additives."
[0109] As used herein, "flavoring agent" adopts its ordinary meaning in food science, but it should be noted that the flavoring agent herein intentionally excludes compounds containing capsaicinoids, which means that the flavoring agent herein does not have a measurable or calculable Scoville heat rating by definition, and is therefore different from the spice additives defined above. The flavoring agent used herein includes, but is not limited to, ethyl maltol, ethyl butyrate, ethyl acetate, maltol, ethyl vanillin, furanol, methylcyclopentenolone, δ-decalactone, γ-decalactone, cis-3-hexanol, isoamyl acetate, ethyl 2-methylbutyrate, butyric acid, linalool, benzyl alcohol, ethyl caproate, benzaldehyde, isoamyl isovalerate, caproic acid, ethyl propionate, γ-undecalactone and hexyl acetate.
[0110] As used herein, the term "about" refers to an amount, level, value, numerical value, frequency, percentage, dimension, size, quantity, weight, or length that differs by 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% from a reference amount, level, value, numerical value, frequency, percentage, dimension, size, quantity, weight, or length. For example, an amount expressed as "about 5% by weight" includes variations of up to 4.5 to 5.5% by weight.
[0111] As used herein, the term "smoking cessation program" refers to a program provided by a medical clinic, pharmacy, or any other commercial enterprise to a current smoker to help the individual quit smoking. In various embodiments, the smoking cessation program herein includes providing an e-cigarette liquid (or providing a disposable electronic device pre-filled with an e-cigarette liquid) to an individual in need, which is designed to help the individual follow the prescribed program and reduce and / or ultimately eliminate smoking. In some examples, the clinic, pharmacy, or other commercial enterprise will meet with individuals who are undergoing a smoking cessation program on a regular basis to inquire about the individual's compliance and provide the individual with a customized vaporizable composition designed to gradually turn the smoker completely to an e-cigarette.
[0112] General Implementation
[0113] The vaporizable alkaloid compositions according to the present disclosure are optimized to provide an improved user experience. The experience of an individual inhaling a vaporized liquid from an electronic device should be similar, if not identical, to the experience of smoking a burning cigarette, but this can only be achieved if certain interrelated sensory effects are balanced, including throat hit, dizziness, nasal and oral sensations and tastes, and cloud appearance. These factors constitute the user experience.
[0114] It has now been surprisingly discovered that the improvement in user experience relies on the unique combination, critical amounts and ratios of substituted pyridine compounds, or salts or mixed salts thereof, and spice additives, which can provide a stronger perceived throat hit than inhaling propylene glycol vapor alone. The vaporizable and inhalable compositions of the present disclosure rely on the precise amounts and ratios of substituted pyridine compounds, or salts or mixed salts thereof, and spice additives. In addition, having at least some of the corresponding organic acid salts of the substituted pyridine compounds in the inhalable compositions reduces irritation and ensures that the user experiences the desired dizziness but with a perceived smoothness.
[0115] In various embodiments, the vaporizable alkaloid composition herein comprises:
[0116] at least one substituted pyridine compound of formula (I) or a salt or mixed salt thereof;
[0117] Where R 1 , R 2 , R3 , R 4 and R 5 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl, provided that if R 5 is CH3, then R 1 , R 2 , R 3 and R 4 Cannot be all H;
[0118] at least one chemosensory stimulant;
[0119] at least one solvent; and,
[0120] Optionally, at least one flavoring agent,
[0121] Wherein, the vaporizable alkaloid composition is completely free of nicotine.
[0122] In various embodiments, at least one chemosensory stimulant is a phytochemical, such as a compound or extract found in Scutellaria baicalensis, such as baicalin, baicalin, wogonin, norwogonin, oxyphyllin A, β-sitosterol.
[0123] In various embodiments, the at least one chemesy stimulant is a spice additive having a pungency of about 1,000 to about 20,000,000 Scoville Heat Units (SHU), such as capsaicin, shogaol, and gingerol.
[0124] Alternatives for these ingredients in the compositions are described below and in the definitions section above, respectively.
[0125] 1. Alkaloid compounds and their salts or mixed salts
[0126] In various embodiments, the vaporizable alkaloid composition herein comprises: at least one substituted pyridine compound of formula (I) or a salt or mixed salt thereof:
[0127]
[0128] Where R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl, provided that if R 5 is CH3, then R 1 , R 2 , R3 and R 4 It cannot be all H. This proviso explicitly excludes the (R) and (S) enantiomers of nicotine from consideration in accordance with the present disclosure. The vaporizable alkaloid compositions of the present disclosure are designed for use in smoking cessation programs and are preferably nicotine-free. Thus, the chemosensory stimulants used in the vaporizable alkaloid compositions herein explicitly exclude the (R) and (S) enantiomers of nicotine, even though nicotine is a known chemosensory stimulant.
[0129] In various embodiments, the vaporizable alkaloid composition according to the present disclosure comprises about 1 wt % to about 80 wt % of the substituted pyridine compound of formula (I) added to the composition. In a more preferred embodiment, the vaporizable alkaloid composition according to the present disclosure comprises about 4 wt % to about 20 wt % of the substituted pyridine compound added to the composition, so as to control the w / v amount of the substituted pyridine compound to about 100 to about 250 mg / mL. In a more preferred embodiment, the vaporizable alkaloid composition according to the present disclosure comprises about 4 wt % to about 12 wt % of the substituted pyridine compound added to the composition, so as to control the w / v amount of the substituted pyridine compound to about 100 mg / mL.
[0130] "Added" refers to a substance that is added to the batch, whether or not any reaction occurs between the components of the composition, such as reaction of a free base alkaloid with an organic acid to form at least some alkaloid salt.
[0131] It should be noted that in formula (I), regardless of R 1 , R 2 , R 3 , R 4 and R 5 Regardless of the choice of , the carbon center of the pyrrolidine ring marked with (*) is always a chiral center.
[0132] In various examples, the substituted pyridine compounds according to formula (I) are racemic mixtures of (R) and (S) at the indicated chiral center (*), such as obtained by achiral synthesis.
[0133] In various examples, the substituted pyridine compounds according to formula (I) are only the (S) enantiomers at the designated chiral center (*), for example, obtained by chiral synthesis or by separation of enantiomers from a racemic mixture. In certain examples, the (S)-substituted pyridine compounds of formula (I) are preferred alkaloids for the vaporizable alkaloid compositions herein.
[0134] In various examples, the substituted pyridine compounds according to formula (I) are only the (R) enantiomer at the designated chiral center (*), for example, obtained by chiral synthesis or by separation of enantiomers. In certain examples, the (R)-substituted pyridine compounds of formula (I) are undesirable alkaloids for the vaporizable alkaloid compositions herein because of their potential adverse physiological effects upon inhalation.
[0135] In various embodiments, and independently of R 5 , R 1 , R 2 , R 3 and R 4 At least one of the R is a methyl group, and the remaining R are not methyl groups. 1 , R 2 , R 3 and R 4 The substituent is H.
[0136] In various embodiments, R 5 is CH3, and R 1 , R 2 , R 3 and R 4 At least one of them is not H.
[0137] In various embodiments, R 1 , R 2 , R 3 , R 4 and R 5 Each is H.
[0138] In various embodiments, R 5 Yes –(CH2)n-NR 6 R 7 , wherein n is an integer from 1 to 10, and R 6 and R 7 are independently selected from: H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl and substituted alkenyl, or R 6 and R 7 Together with the N atom to which it is bonded, it forms a 3-8 membered optionally substituted heterocyclic ring, including, for example, aziridine, azetidine, pyrrolidine, piperidine, 1,4-piperazine and morpholine. 1 , R 2 , R 3 and R 4 , R 5Selected from -(CH2)-NH2; -(CH2)2-NH2; -(CH2)3-NH2; -(CH2)4-NH2; -(CH2)5-NH2; -(CH2)6-NH2; -(CH2)7-NH2; -(CH2)8-NH2; -(CH2)9-NH2; -(CH2) 10 -NH2; -(CH2)-N(CH3)2; -(CH2)2-N(CH3)2; -(CH2)3-N(CH3)2; -(CH2)4-N(CH3)2; -(CH2)5-N (CH3)2; -(CH2)6-N(CH3)2; -(CH2)7-N(CH3)2; -(CH2)8-N(CH3)2; -(CH2)9-N(CH3)2; and -(CH2) 10 -N(CH3)2.
[0139] In various embodiments, independent of R 1 , R 2 , R 3 and R 4 , R 5 Selected from:
[0140] Where n is 1-10;
[0141] Where n is 1-10;
[0142] Where n is 1-10;
[0143] Where n is 1-10; and
[0144] Where n is 1-10; R 8 is selected from the group consisting of H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl.
[0145] In various embodiments, independent of R 1 , R 2 , R 3 and R 4 , R 5 yes:
[0146] wherein n is 1-10; and R 8 It is H or CH3.
[0147] In various embodiments, R 5 is H, and R 1 , R 2 , R 3 and R4 At least one of them is -(CH2)n-NR 6 R 7 , wherein n is an integer from 1 to 10, and R 6 and R 7 is independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl and substituted alkenyl, or R 6 and R 7 Together with the nitrogen atom to which they are bound, they form a 3-8 membered optionally substituted heterocyclic ring.
[0148] In various embodiments, R 5 is CH3, and R 1 , R 2 , R 3 and R 4 At least one of them is -(CH2)n-NR 6 R 7 , wherein n is an integer from 1 to 10, and R 6 and R 7 is independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl and substituted alkenyl, or R 6 and R 7 Together with the nitrogen atom to which they are bound, they form a 3-8 membered optionally substituted heterocyclic ring.
[0149] In various embodiments, R 5 is CH3, and R 1 , R 2 , R 3 and R 4 At least one of them is -(CH2)nN(CH3)2, wherein n is an integer from 1 to 10.
[0150] In various embodiments, the substituted pyridine compounds of formula (I) used in the vaporizable alkaloid compositions herein include, but are not limited to: (R) or (S)-3-(pyrrolidin-2-yl)pyridine, (R) or (S)-2-methyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-4-methyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-3-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)- -2,6-dimethyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2,4-dimethyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2,3-dimethyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2,4-dimethyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2,5-dimethyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-3,4-dimethyl-5-(1-methylpyrrolidin-2-yl)pyridine, ( R) or (S) -1-(2-aminoethyl)-2-(3-pyridyl)pyrrolidine, (R) or (S) -1-(3-aminopropyl)-2-(3-pyridyl)pyrrolidine, (R) or (S) -1-(4-aminobutyl)-2-(3-pyridyl)pyrrolidine, (R) or (S) -1-(5-aminopentyl)-2-(3-pyridyl)pyrrolidine, (R) or (S) -1-(2-dimethylaminoethyl)-2-(3-pyridyl)pyrrolidine, (R) or (S) -1-(3-dimethylaminopropyl)-2-(3-pyridyl)pyrrolidine, (R) or (S) -1-(4-aminobutyl)-2-(3-pyridyl)pyrrolidine, (R) or (S) -1-(5-aminopentyl)-2-(3-pyridyl)pyrrolidine, (R) or (S) -1-(2-dimethylaminoethyl)-2-(3-pyridyl)pyrrolidine, (R) or (S) -1-(3-dimethylaminopropyl)-2-(3-pyridyl)pyrrolidine, (R) ) or (S) -1-(4-dimethylaminobutyl)-2-(3-pyridyl)pyrrolidine, (R) or (S) -3-(2-(6-methylpyridin-3-yl)pyrrolidin-1-yl)propionitrile, (R) or (S) -4-(2-(6-methylpyridin-3-yl)pyrrolidin-1-yl)butyronitrile, (R) or (S) -1-(3-aminopropyl)-2-(6-methyl-3-pyridyl)pyrrolidine, (R) or (S) -1-[3-(N,N-dimethylamino)propyl]-2-(6-methyl-3-pyridyl)pyrrolidine, (R) or (S) -1-(N,N-diethyl-3-aminopropyl-2-(3-pyridyl)pyrrolidine, (R) or (S)-3-(1-(2-(pyrrolidin-1-yl)ethyl)pyrrolidin-2-yl)pyridine, (R) or (S)-3-(1-(2-(piperidin-1-yl)ethyl)pyrrolidin-2-yl)pyridine, (R) or (S)-4-(2-(2-(pyridin-3-yl)pyrrolidone) (R) or (S)-3-(1-(3-(pyrrolidin-1-yl)propyl)pyrrolidin-2-yl)pyridine, (R) or (S)-3-(1-(3-(piperidin-1-yl)propyl)pyrrolidin-2-yl)pyridine and (R) or (S)-4-(3-(2-(pyridin-3-yl)pyrrolidin-1-yl)propyl)morpholine.
[0151] In various embodiments, the substituted pyridine compounds of formula (I) used in the vaporizable alkaloid composition herein also include, but are not limited to:
[0152]
[0153]
[0154]
[0155]
[0156]
[0157]
[0158]
[0159]
[0160]
[0161]
[0162]
[0163]
[0164]
[0165]
[0166]
[0167]
[0168] and
[0169]
[0170] In each of the above examples, the (S) enantiomer may be active as a nicotinic acetylcholine receptor ligand and is preferred, while the (R) enantiomer may be physiologically inert or even metabolically toxic. Therefore, in preferred embodiments, no racemic mixture of any of these alkaloids is used.
[0171] In various embodiments, R 1 , R 2 , R 3 , R 4 and R 5 independently selected from H, methyl, ethyl, n-propyl, isopropyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, provided that if R 5 is methyl, then R 1 , R 2 , R 3 and R 4 It can’t be all H.
[0172] In a preferred example, R 1 and R 5 All are methyl, R 2 , R 3 and R 4 All are H, and the chiral center (*) is in the (S)-configuration.
[0173] Of particular interest in the compositions of the present invention is (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, a compound having the chemical structure (1) or a salt thereof or a mixture thereof:
[0174]
[0175] CG Chavdarian et al. disclosed a chiral synthesis of alkaloid (1) in U.S. Pat. No. 4,321,387 issued to Philip Morris, Inc. in 1982. The compound can be prepared by the synthetic route of Philip Morris, or by another suitable chiral synthetic route known or designed by one skilled in the art, or obtained from a commercial supplier, such as Toronto Research Chemicals, Toronto, Ontario, Canada, catalog number M323270.
[0176] Salts or mixed salts of the alkaloids of formula (I) can be used herein and can be prepared by reacting the substituted pyridine compound (I) with an inorganic acid or preferably an organic acid R 9-CO2H or a mixture of organic acids in a suitable solvent, under ambient reaction conditions or under heating to obtain. R is selected accordingly according to the desired corresponding organic acid. 9 (For example, for formic acid, R 9 =H, for acetic acid, R 9 =CH3, for citric acid, R 9 =-CH(CO2H)-CH2-CO2H, etc.), so R 9 is selected from alkyl, cycloalkyl, aryl and heterocyclyl, any of which may be optionally substituted.
[0177] Reaction Scheme A illustrates the general synthesis of alkaloid salts for use in the vaporizable alkaloid compositions of the present disclosure when an organic acid is used rather than an inorganic acid:
[0178] Reaction Scheme A - General Synthesis of Alkaloid Salts
[0179] In the above reaction scheme A, although one may know precisely the composition of the free base alkaloid (I) and the acid R 9 -CO2H or acid mixtures, but no attempt was made to quantify or characterize the resulting salt or salt mixtures (Ia) or to quantify the completeness of the reaction, since it is recognized that some organic acids are not just monobasic acids but can also act as chelating agents. Various acid-base ratios can be formed (i.e., salts with acid-base ratios other than 1:1). For example, T.A. Perfetti, in Structural Study of Nicotine Salts ( zur Tabakforschung International, 12(2), 43-54, 1983) describes nicotine salts made from various organic acids, wherein the acid-base ratio of nicotine is 1:1, 2:1 and 3:1. In this reference, Perfetti discloses that nicotine forms a 3:1 acid-base salt with an aliphatic monocarboxylic acid (e.g., acetic acid), wherein one acid molecule is bound as in a 1:1 salt, and the other two acid molecules are bound to the nitrogen of the pyridine ring, whereas benzoate is a 1:1 acid-base salt. Perfetti discloses that the citrate of nicotine is a 2:1 acid-base salt. Thus, if R 9 -CO2H represents a mixture of organic acids, and the resulting alkaloid salt (Ia) may not be characterized.
[0180] In the above reaction scheme A, the organic acid R 9-CO2H can be any acid disclosed herein, including formic acid, acetic acid, trifluoroacetic acid, aspartic acid, butanoic acid, butyric acid, 2-methylbutyric acid, 3-methylbutyric acid, benzoic acid, caprylic acid, citric acid, crotonic acid, ethylenediaminetetraacetic acid, fumaric acid, gluconic acid, glutamic acid, glyceric acid, glycolic acid, lactic acid, lauric acid, levulinic acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, oxalic acid, phenylacetic acid, phthalic acid, picric acid, propionic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, tartronic acid, valeric acid and mixtures thereof. Preferred for use herein are citric acid, acetic acid, benzoic acid, tartaric acid, lactic acid, salicylic acid, malic acid, levulinic acid and mixtures thereof.
[0181] In the above reaction scheme A, the solvent can be selected based on whether it is suitable for the composition intended to be evaporated and inhaled, i.e., pharmaceutically acceptable or otherwise considered "safe". In other words, it is recognized that the acid / base reaction can be carried out in situ, and the alkaloid salt (Ia) will not be separated, but the resulting reaction mixture becomes an evaporable alkaloid composition according to the present disclosure. In these cases, the solvent is selected from the group consisting of propylene glycol, glycerol, ethanol, water and mixtures thereof. Typically, reaction scheme A can be carried out in a solvent mixture of propylene glycol / ethanol and a small amount of water (e.g., water entrained in the reaction when 190 degree ethanol is used). If desired, the final reaction mixture can be cooled and filtered before being used in electronic devices.
[0182] In a preferred embodiment, a deficiency of the organic acid R is used in reaction scheme A (or in the composition if carried out in situ). 9 -CO2H, so that a mixture of alkaloid salt and unreacted alkaloid free base is produced and thus remains together in the vaporizable alkaloid composition. In a less preferred embodiment, a sufficient amount or excess of organic acid R is used in the reaction. 9 -CO2H to drive the salt formation to completion, making it possible for no free base alkaloid to remain.
[0183] In various embodiments, it is preferred to provide a molar excess of the substituted pyridine free base compound relative to the one or more organic acids so that the formation of the alkaloid salt is incompletely reacted and the vaporizable alkaloid composition comprises the alkaloid organic acid salt and unreacted alkaloid free base.
[0184] In various embodiments, typical amounts of a given substituted pyridine compound are from about 1 wt % to about 80 wt %, and the vaporizable alkaloid compositions herein comprise from about 0.05 wt % to about 1.5 wt %, preferably from about 0.05 wt % to about 0.15 wt % of total organic acids, based on the total weight of the composition.
[0185] In various embodiments, the substituted pyridine free base compound and the total organic acid R 9 The molar ratio of -CO2H is from about 25:1 to about 75:1, more preferably about 50:1. This ratio can be kept constant so that in the composition with increasing amounts of the substituted pyridine free base compound, the total organic acid R 9 The amount of -CO2H can also be increased to maintain this molar ratio.
[0186] It is emphasized that when using the substituted pyridine compound in the vaporizable alkaloid composition, it is not necessary to isolate any desired salt. The vaporizable alkaloid composition can be prepared by mixing the substituted pyridine free base compound with the desired organic acid in a solvent system, wherein the alkaloid salt is formed in situ, and the reaction mixture thus formed is the vaporizable alkaloid composition.
[0187] In various preferred embodiments, (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine is reacted with an organic acid selected from the group consisting of acetic acid, benzoic acid, citric acid, lactic acid, levulinic acid, malic acid, salicylic acid, tartaric acid, and mixtures thereof. In more preferred embodiments, (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine is reacted with a combination of citric acid and acetic acid in a molar deficit.
[0188] For the vaporizable alkaloid compositions of the present disclosure, preferred salts and mixed salts of the substituted pyridine compounds of formula (I) include, but are not limited to:
[0189] (2S)-1-methyl-2-(6-methylpyridin-3-yl)pyrrolidin-1-ium acetate,
[0190] (2S)-1-methyl-2-(5-methylpyridin-3-yl)pyrrolidin-1-ium acetate,
[0191] (2S)-1-methyl-2-(4-methylpyridin-3-yl)pyrrolidin-1-ium acetate,
[0192] (2S)-1-methyl-2-(2-methylpyridin-3-yl)pyrrolidin-1-ium acetate,
[0193] (2S)-2-(2,4-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium acetate,
[0194] (2S)-2-(2,5-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium acetate,
[0195] (2S)-2-(2,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium acetate,
[0196] (2S)-2-(4,5-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium acetate,
[0197] (2S)-2-(4,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium acetate,
[0198] (2S)-2-(5,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium acetate,
[0199] (2S)-1-methyl-2-(6-methylpyridin-3-yl)pyrrolidin-1-ium citrate,
[0200] (2S)-1-methyl-2-(5-methylpyridin-3-yl)pyrrolidin-1-ium citrate,
[0201] (2S)-1-methyl-2-(4-methylpyridin-3-yl)pyrrolidin-1-ium citrate,
[0202] (2S)-1-methyl-2-(2-methylpyridin-3-yl)pyrrolidin-1-ium citrate,
[0203] (2S)-2-(2,4-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium citrate,
[0204] (2S)-2-(2,5-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium citrate,
[0205] (2S)-2-(2,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium citrate,
[0206] (2S)-2-(4,5-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium citrate,
[0207] (2S)-2-(4,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium citrate,
[0208] (2S)-2-(5,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium citrate,
[0209] (2S)-1-methyl-2-(6-methylpyridin-3-yl)pyrrolidin-1-ium citrate / acetate,
[0210] (2S)-1-methyl-2-(5-methylpyridin-3-yl)pyrrolidin-1-ium citrate / acetate,
[0211] (2S)-1-methyl-2-(4-methylpyridin-3-yl)pyrrolidin-1-ium citrate / acetate,
[0212] (2S)-1-methyl-2-(2-methylpyridin-3-yl)pyrrolidin-1-ium citrate / acetate,
[0213] (2S)-2-(2,4-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium citrate / acetate,
[0214] (2S)-2-(2,5-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium citrate / acetate,
[0215] (2S)-2-(2,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium citrate / acetate,
[0216] (2S)-2-(4,5-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium citrate / acetate,
[0217] (2S)-2-(4,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium citrate / acetate,
[0218] (2S)-2-(5,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium citrate / acetate,
[0219] (2S)-1-methyl-2-(6-methylpyridin-3-yl)pyrrolidin-1-ium benzoate,
[0220] (2S)-1-methyl-2-(5-methylpyridin-3-yl)pyrrolidin-1-ium benzoate,
[0221] (2S)-1-methyl-2-(4-methylpyridin-3-yl)pyrrolidin-1-ium benzoate,
[0222] (2S)-1-methyl-2-(2-methylpyridin-3-yl)pyrrolidin-1-ium benzoate,
[0223] (2S)-2-(2,4-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium benzoate,
[0224] (2S)-2-(2,5-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium benzoate,
[0225] (2S)-2-(2,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium benzoate,
[0226] (2S)-2-(4,5-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium benzoate,
[0227] (2S)-2-(4,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium benzoate,
[0228] (2S)-2-(5,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium benzoate,
[0229] (2S)-1-methyl-2-(5-methylpyridin-3-yl)pyrrolidin-1-ium ditartrate,
[0230] (2S)-1-methyl-2-(4-methylpyridin-3-yl)pyrrolidin-1-ium ditartrate,
[0231] (2S)-1-methyl-2-(2-methylpyridin-3-yl)pyrrolidin-1-ium ditartrate,
[0232] (2S)-2-(2,4-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium ditartrate,
[0233] (2S)-2-(2,5-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium ditartrate,
[0234] (2S)-2-(2,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium ditartrate,
[0235] (2S)-2-(4,5-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium ditartrate,
[0236] (2S)-2-(4,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium ditartrate,
[0237] (2S)-2-(5,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium ditartrate,
[0238] (2S)-1-methyl-2-(5-methylpyridin-3-yl)pyrrolidin-1-ium lactate,
[0239] (2S)-1-methyl-2-(4-methylpyridin-3-yl)pyrrolidin-1-ium lactate,
[0240] (2S)-1-methyl-2-(2-methylpyridin-3-yl)pyrrolidin-1-ium lactate,
[0241] (2S)-2-(2,4-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium lactate,
[0242] (2S)-2-(2,5-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium lactate,
[0243] (2S)-2-(2,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium lactate,
[0244] (2S)-2-(4,5-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium lactate,
[0245] (2S)-2-(4,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium lactate,
[0246] (2S)-2-(5,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium lactate,
[0247] (2S)-1-methyl-2-(5-methylpyridin-3-yl)pyrrolidin-1-ium levulinate,
[0248] (2S)-1-methyl-2-(4-methylpyridin-3-yl)pyrrolidin-1-ium levulinate,
[0249] (2S)-1-methyl-2-(2-methylpyridin-3-yl)pyrrolidin-1-ium levulinate,
[0250] (2S)-2-(2,4-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium levulinate,
[0251] (2S)-2-(2,5-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium levulinate,
[0252] (2S)-2-(2,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium levulinate,
[0253] (2S)-2-(4,5-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium levulinate,
[0254] (2S)-2-(4,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium levulinate,
[0255] (2S)-2-(5,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium levulinate,
[0256] (2S)-1-methyl-2-(4-methylpyridin-3-yl)pyrrolidin-1-ium malate,
[0257] (2S)-1-methyl-2-(2-methylpyridin-3-yl)pyrrolidin-1-ium malate,
[0258] (2S)-2-(2,4-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium malate,
[0259] (2S)-2-(2,5-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium malate,
[0260] (2S)-2-(2,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium malate,
[0261] (2S)-2-(4,5-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium malate,
[0262] (2S)-2-(4,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium malate,
[0263] (2S)-2-(5,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium malate,
[0264] (2S)-1-methyl-2-(4-methylpyridin-3-yl)pyrrolidin-1-ium salicylate,
[0265] (2S)-1-methyl-2-(2-methylpyridin-3-yl)pyrrolidin-1-ium salicylate,
[0266] (2S)-2-(2,4-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium salicylate,
[0267] (2S)-2-(2,5-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium salicylate,
[0268] (2S)-2-(2,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium salicylate,
[0269] (2S)-2-(4,5-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium salicylate,
[0270] (2S)-2-(4,6-dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium salicylate and
[0271] (2S)-2-(5,6-Dimethylpyridin-3-yl)-1-methylpyrrolidin-1-ium salicylate.
[0272] In various embodiments, the vaporizable alkaloid composition of the present invention comprises from about 1 wt% to about 20 wt% of at least one substituted pyridine compound of formula (I) or its salt or its mixed salt, based on the total weight of the vaporizable alkaloid composition, more preferably from about 4 wt% to about 12 wt% of at least one substituted pyridine compound of formula (I) or its salt or its mixed salt. In a preferred embodiment, the amount of the substituted pyridine compound of formula (I) in the vaporizable alkaloid composition can be targeted to be 100 mg / mL (w / v), recognizing that such a composition can always be diluted (even by the end user) using an acceptable solvent (e.g., PG and / or VG), so that the actual composition used by individuals in electronic devices may have an alkaloid content (w / v) of less than 100 mg / mL.
[0273] In a more preferred embodiment, the vaporizable alkaloid composition herein comprises about 4 wt % to about 12 wt % (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, based on the total weight of the vaporizable alkaloid composition, and is added to the composition.
[0274] 1a. Alternative alkaloids
[0275] In other embodiments of the present disclosure, the vaporizable alkaloid composition herein comprises at least one substituted pyridine compound of formula (II) or a salt or mixed salt thereof:
[0276]
[0277] Where R 1 , R 2 , R 3 , R 4 , R 10 , R 11 and R 12 is independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl; and n is an integer from 1 to 10.
[0278] In various embodiments, R 11 and R 12 All are H.
[0279] In various embodiments, R 11 is CH3, and R 12 For H.
[0280] In various embodiments, R 11 and R 12 All are CH3.
[0281] In various embodiments, n is an integer from 1 to 4.
[0282] Preferred R 1 , R 2 , R 3 and R 4 The substituents are the same as defined above in the compounds of formula (I).
[0283] In various examples, the substituted pyridine compounds of formula (II) used in the vaporizable alkaloid compositions of the present disclosure include, but are not limited to:
[0284]
[0285]
[0286]
[0287]
[0288] and
[0289]
[0290] 2. Chemical sensory stimulants
[0291] The chemosensory stimulants for the vaporizable alkaloid compositions of the present disclosure include any natural, endogenous, phytochemical or synthetic compounds capable of activating TRP ion channels, including those derived from naturally occurring compounds by organic chemistry. For example, HP Fallah et al. found a detection method that can be used to determine whether a compound is indeed a TRP ion channel activator in the article "A Review on the Role of TRP Channels and Their Potential as Drug Targets: An Insight Into the TRP Channel Drug Discovery Methodologies" (Front. Pharmacol., 202213: 914499).
[0292] The chemosensory stimulants used herein include, but are not limited to, oleocanthal, 4-hydroxy-2-nonenal, 4-oxo-2-nonenal, allicin, allyl isothiocyanate, icilin, polygodial, cinnamaldehyde, trans-p-methoxycinnamaldehyde, methyl syringate, 2-chlorobenzylidenemalononitrile, 1-chloroacetophenone, ethyl bromoacetate, 4-hydroxyhexenal, toluene. diisocyanates, p-benzoquinone, methyl paraben, flufenamic acid, niflumic acid, mefenamic acid, diclofenac, hydroxy-α-sanshool, paradol, linalool, carvacrol, eugenol, thymol, vanillin, methyl eugenol, 2,6-dimethylphenol, 2,5-dimethylphenol, 3,4-dimethylphenol, 2,6-diisopropylphenol, caffeine, farnesyl thiosalicylic acid, 4-allyl anisole, curcumin, niacin, camphor, olvanil and arvanil, anandamide (AEA), 2-AG, NADA, OLDA, PEA, NGABA, NGly, NAsp, NSer, Δ 9 -THCA, Δ 9 -THCV, Δ 9-THCVA, CBD, CBDA, CBDV, CBG, CBGA, CBGV, CBN, CBC, WIN55,212-2, AM630, (R)-AM1241, (S)-AM1241, SR141716A, Gp-1a, AM251, SR144528, JWH133, HU308, HU910, CP55,940, Nabilon, various phytochemicals from Euphorbia reinifera, Euenia carophyllata, Ocimum gratissium, Panax ginseng, Aframomum melgueta, Evodiarutaecarpa, Drymis winteri, Cinnamosma fragrans, Warburgia, Scutellaria baicalensis, Vitex agnus, Pterodon pubescens, Croton macrostachyus, Angelica epubescentis, Ephedrasinica, Amphilophium crucigerum, Bosewellia carterii, Commiphora myrrha, Echinophora platyloba, Nypa fruticans, Corydalis saxicola, Coptis chinensis, Ononis spinosa, Parkia platycephala, and Cymbopogon citratus, as well as a subset of all chemesy stimuli of spice additives individually defined as having a pungency of from about 1,000 SHU to about 20,000,000 SHU. Many of the spice additives used in this article are phytochemicals found in various herbs and fruits, such as compounds in chili peppers, ginger, and pepper.
[0293] According to various embodiments, the spice additive used as a chemosensory stimulant in the vaporizable alkaloid composition of the present disclosure is an organic compound having a pungency or heat of about 1000 to about 20,000,000 Scoville heat units (SHU), more preferably about 100,000 to about 20,000,000 Scoville heat units (SHH). Therefore, the spice additive for the purposes of this article is a defined group of compounds. The calculation method of Scoville heat units is shown in the American Spice Trade Association (ASTA) 1985 "Official Analytical Methods of the American Spice Trade Association" (Official Analytical Methods of the American Spice Trade Association) 3rd Edition, American Spice Trade Association, Englewood Cliffs, NJ.
[0294] In various embodiments, the spice additive herein comprises capsaicinoids or a mixture of capsaicinoids. In certain instances, the liquid extract comprises a mixture of capsaicinoids prepared by solvent extraction of a pepper known to contain a mixture of capsaicinoids rather than just capsaicinoids. In other embodiments, capsaicinoids are sourced and used.
[0295] In other examples, spice additives are used that are chemically unrelated to capsaicinoids but still have a measurable heat level reported in Scoville units. These compounds are often extracted from peppers other than Capsicum annuum, such as black pepper (Pipernigrum L.), and the most useful spice additive is not capsaicinoids, but piperine (E, E, or trans-trans isomers). Other spice additives other than capsaicin for use herein include, but are not limited to, shogaol, gingerol, isopiperine, chavicine, isochavicine, 2-piperamine, piperanine (4,5-dihydropiperine), piperonamide, 4-pipericide, piperyline, piperlonguminine, piperettine, piperdardine (6,7-dihydropiperettine), 5-sarmentodine, 6-sarmentine, and 7-trichostachine.
[0296] In various embodiments, the spice additive is selected from the group consisting of capsaicin, dihydrocapsaicin, norcapsaicin, nordihydrocapsaicin, homocapsaicin, homodihydrocapsaicin, gingerol, piperine, shogaol, and mixtures thereof. Other capsaicinoids other than these six defined capsaicinoids may also be used in the compositions herein, noting that at least seven different capsaicinoids have been described in the genus Capsicum annuum, and that it is possible that two of them (possibly capsaicin and dihydrocapsaicin) together are the capsaicinoids responsible for the spicy flavor of chili peppers. See MD Collins et al., "Improved Method for Quantifying Capsaicinoids in Capsicum Using High-Performance Liquid Chromatography," Hort Science 30(1): 137-139, 1995. While the above compounds belong to the general class of chemessay irritants, these compounds are conveniently grouped into a subset of chemessay irritants defined as spice additives having a pungency of from about 1,000 to about 20,000,000 Scoville Heat Units (SHU).
[0297] In various embodiments, the vaporizable alkaloid composition herein comprises from about 0.0001 wt % to about 0.5 wt % of a spice additive, based on the total weight of the vaporizable alkaloid composition, wherein the spice additive exhibits a spiciness or heat of from about 1,000 to about 20,000,000 Scoville heat units (SHU). For spice additives having a spiciness greater than about 10,000,000 SHU, the amount can be significantly reduced, for example, from about 0.0001 wt % to about 0.01 wt % of the spice additive, based on the total weight of the composition.
[0298] In a preferred embodiment, the vaporizable alkaloid composition herein includes capsaicin ((E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide, CAS No.: 404-86-4). Capsaicin in pure form (100% active) is a white crystalline solid with an MP of 65° C. The purified material can be used directly in the composition herein, for example, it can be obtained from chemical suppliers such as Sigma-Aldrich Co., VWR Avantor and AlfaChemistry.
[0299] In a preferred embodiment, the vaporizable alkaloid composition herein comprises about 0.0001 wt % to about 0.01 wt % of capsaicin ((E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide) based on the total weight of the vaporizable alkaloid composition. In a more preferred embodiment, the amount of capsaicin is about 0.0005 wt % to about 0.0015 wt % based on the total weight of the composition.
[0300] In various examples, "liquid capsaicin" is used in the vaporizable alkaloid compositions herein, for example, for cost and practicality reasons. For example, a chili pepper flavor extract can be used, which can be purchased from Olive Nation, LLC, Avon, MA in quantities ranging from gallons to barrels. This product is an ethanol extract of chili peppers, with a distinct reddish-brown appearance and a specific gravity of about 0.8 g / mL at 20°C. This commercial material is about 99.1% by weight ethanol and about 0.9% by weight total alkaloid active substances of chili peppers.
[0301] In various embodiments, the vaporizable alkaloid compositions herein comprise from about 0.05 wt % to about 0.15 wt % capsaicinoid liquid (e.g., a chili flavor extract produced by Olive Nation having about 0.9 wt % total active capsaicinoids) based on the total weight of the vaporizable alkaloid composition.
[0302] 3. Solvent
[0303] In various embodiments, the vaporizable alkaloid composition herein comprises at least one solvent. The solvent in the vaporizable composition to be vaporized and inhaled by a person includes, but is not limited to, propylene glycol, water, ethanol, glycerol, and mixtures thereof. As can be seen from the exemplary compositions herein, water may be mixed in a composition comprising aqueous ethanol (e.g., 190 degree ethanol). Similarly, additional ethanol (e.g., total capsaicin in ethanol) may be added to a composition utilizing a capsaicin liquid.
[0304] In various embodiments, the vaporizable alkaloid composition herein comprises about 85 wt % to about 99.9 wt % total solvent, based on the total weight of the vaporizable alkaloid composition. In certain instances, the solvent comprises mostly vegetable glycerin, and small amounts of propylene glycol and ethanol (and trace amounts of water).
[0305] In various embodiments, the vaporizable alkaloid composition herein comprises a mixture of solvents, the solvent comprising from about 85.0 wt % to about 95.0 wt % vegetable glycerin and from about 0.5 wt % to about 3 wt % propylene glycol, based on the total weight of the composition. In certain instances, the amount of total solvent (regardless of composition) may be expressed as a "sufficient amount" or "qs," which is the amount of solvent required to bring the total amount of the composition to 100 wt %.
[0306] 4. Optional flavoring
[0307] In various embodiments, the vaporizable alkaloid composition of the present invention may optionally contain up to about 1.0% by weight of at least one flavoring agent based on the total weight of the composition. The weight percentage of the flavoring agent used in the composition of the present invention will vary greatly depending on the flavor type and the desired sensory results. In some cases, the amount used will be much less than 1.0% by weight (e.g., 0.1% by weight or less). The optional flavoring agents used herein include, but are not limited to, geraniol, geranyl, valeric acid, methyl salicylate, ethyl maltol, ethyl butyrate, ethyl acetate, maltol, ethyl vanillin, 3-methyl-3-phenylglycidic acid ethyl ester, furanol, methylcyclopentenolone, methylcyclopentenolone, ethylcyclopentenolone, δ-decalactone, γ-decalactone, α-nonalactone, β-nonalactone, cis-3-hexanol, isoamyl acetate, ethyl 2-methylbutyrate, butyric acid, ethyl butyrate, 2-methylbutyric acid, benzyl alcohol, ethyl cyclopentenolone ...ethyl cyclopentenolone, δ-decalactone, γ-decalactone, α-nonalactone, β-nonalactone, cis-3-hexanol, isoamyl acetate, ethyl 2-methylbutyrate, butyric acid, ethyl butyrate, 2-methylbut Methanol, ethyl hexanoate, benzaldehyde, isopentyl isovalerate, hexanoic acid, ethyl propionate, γ-undecalactone, levulinyl, raspberry ketone, furfural, 5-methylfurfural, maltol, 2-acetylpyrazine, 2,3,5-trimethylpyrazine, 2-acetylpyrrole, 2-isopropyl-4-methylthiazole, 2-isobutylthiazole, furfurylthiol, thiomenthone, p-menthene-8-thiol, 2-methyl-4-propyl-1,3-tropathiane, hexyl acetate and mixtures thereof.
[0308] Exemplary compositions
[0309] In various embodiments, the vaporizable alkaloid composition of this invention comprises at least one substituted pyridine compound of formula (I) or its salt or mixed salt and chemical sensory stimulant in a suitable solvent. In various examples, the chemical sensory stimulant comprises a spice additive having a pungency of about 1,000 to about 20,000,000 SHU. In various examples, the composition further comprises at least one organic acid, thereby converting at least some substituted pyridine compounds of formula (I) into their corresponding salt or mixed salt. The resulting composition is a thin, transparent and uniform liquid.
[0310] Table 1 provides general embodiments of vaporizable alkaloid compositions according to the present disclosure.
[0311] Table 1: Overview of vaporizable alkaloid compositions Element Weight Percentage (wt%) <![CDATA[Substituted pyridine compound of formula (I) 1 > 1 wt % to about 80 wt % <![CDATA[Organic acid 2 > 0.05 wt % to about 1.5 wt % <![CDATA[Chemosensory stimuli 3 > 0.0001 wt % to about 0.5 wt % <![CDATA[Flavoring agent 4 > 0 wt % to about 1 wt % <![CDATA[Solvent 5 > qs total 100.00% by weight
[0312] Note 1: The compositions according to Table 1 are designed to target a certain w / v level of substituted pyridine compound in the finished composition, such as 1000 mg / mL, 750 mg / mL, 500 mg / mL, 250 mg / mL, or 100 mg / mL. As described herein, the compositions in Table 1 having these relatively high levels of substituted pyridine compound (e.g., ≥ 100 mg / mL) can be considered concentrates and, therefore, can be further diluted by a third party manufacturer or compounder, or even potentially by an end user who refills a refillable electronic device.
[0313] Note 2: In the preferred composition of Table 1, the substituted pyridine free base and the total organic acid R 9 The molar ratio of -CO2H is from about 25: 1 to about 75: 1, more preferably about 50: 1. Therefore, it is expected that in any composition given the above weight percentage ranges, most of the substituted pyridine compound of formula (I) will remain as a free base, regardless of the molecular weight of the free base alkaloid and the organic acid.
[0314] Note 3: In these compositions, the preferred range of spice additives in the compositions, normalized for capsaicinoid activity, is from about 0.0001 wt % to about 0.01 wt %, whereas the broader range provided in Table 1, i.e., from about 0.0001 wt % to about 0.5 wt %, reflects a general range that includes any of the above-mentioned chemosensory stimulants, including a subset of spice additives that are not necessarily capsaicinoids. The amount of chemosensory stimulant used in the vaporizable alkaloid composition can be based on the TRP channel activator EC that is measured. 50 or [A] 50The EC50 value is adjusted, which is the molar concentration of the activator that produces 50% of the maximum possible effect of the activator. A chart of human TRP receptor activators and their EC50 values can be found, for example, in L. Premkumar, "Transient Receptor Potential Channels as Targets of Phytochemicals", ACS Chem. Neurosci., 5 (11) 1117-1130, 2014, and R. Neubig et al., "International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology", Pharmacological Reviews, 55 (4), 597-606 (2003). The phytochemicals disclosed by Premkumar are incorporated herein by reference to clarify their use in the vaporizable alkaloid compositions disclosed herein.
[0315] When a spice additive is selected as a chemosensory stimulant, the amount (wt%) of the spice additive can be adjusted accordingly to obtain a lower or higher pungency than capsaicin (< or > 16,000,000 SHU). In other words, alternative spice additives for capsaicin can be standardized to capsaicin. As a rough estimate, the ratio of the SHU of the alternative spice additive to the SHU of capsaicin (16,000,000 SHU) can be used to calculate the reasonable amount of different spice additives that replace capsaicin. For example, gingerol (160,000 SHU) can be used at 100 times the preferred range of 0.0001 wt% to about 0.01 wt% of active capsaicin (16,000,000 SHU) because the ratio of Scoville numbers is 16,000,000 SHU / 160,000 SHU=100. Therefore, based on the total weight of the composition, the suitable range of gingerol active substances in the composition can be 0.01 wt% to about 1 wt% gingerol. If a spice additive with a heat level greater than 16,000,000 SHU is used, less spice additive will be added. Focus groups and sensory panels can certainly help refine these estimated ranges, but being able to calculate in this way represents a starting point. The ability to swap spice additives is particularly useful if there are supply / cost issues with a particular spice additive, or if some users desire a different sensory experience. Additionally, if a liquid extract is used instead of an active spice additive, such as liquid capsaicin, the weight percent of the spice additive active in the composition of Table 1 is increased accordingly.
[0316] Note 4: In these compositions, flavoring is optional in that it can be added later if desired, for example if the composition of Table 1 is diluted by a third party provider or by an end user who is able to fill a refillable device. Thus, for example, a composition according to Table 1 may start out with no flavoring added, and then the third party or end user may dilute the composition (e.g., with VG and / or PG) and add a flavoring of their own choice.
[0317] Note 5: In these compositions, the solvent is selected in part based on inhalation acceptability because the composition will ultimately be used in an electronic cigarette device. Therefore, the solvents in Table 1 are generally selected from the group consisting of propylene glycol, glycerol, ethanol, water, and mixtures thereof. Each composition may contain a majority of propylene glycol, a majority of vegetable glycerol, or a mixture of the two as the major portion of the solvent component. As mentioned, a third party or end user may further dilute the composition of Table 1 and may choose to use propylene glycol, vegetable glycerol, or a mixture thereof (e.g., 50 / 50 VG / PG) for this purpose. It is further noteworthy that in the case of a high content of the substituted pyridine compound of formula (I) (e.g., greater than about 20 wt%), the solubility of the alkaloid may be problematic, in which case the solvent ratio is adjusted to improve solubility, for example by increasing the ethanol weight % and reducing the glycerol and / or propylene glycol weight %. In general, the substituted pyridine compound of formula (I) is more likely to be soluble in ethanol than in VG or PG. Compositions having from about 4 wt % to about 12 wt % of a substituted pyridine compound of formula (I) are generally homogeneous with a mixture of VG / PG and very small amounts of ethanol.
[0318] Table 2 lists embodiments of vaporizable alkaloid compositions according to the present disclosure. The compositions are derived from the general embodiments presented in Table 1, wherein the chemosensory stimulants are selected from a subset known as spice additives, and the annotations to Table 1 above have been shown to be both vaporizable as shown or diluted to a lower w / v alkaloid and acceptable to consumers. The exemplary compositions in Table 2 are merely examples and should not be considered to limit the scope of the present disclosure in any way. For example, other substituted pyridine compounds of formula (I) can be used in place of (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, other organic acids can be used in addition to citric acid and acetic acid, and other chemosensory stimulants other than spice additives can be used to provide a perceptible throat hit. In addition, the relative amounts of solvents in each composition can also be varied to increase solubility.
[0319] Table 2: Exemplary vaporizable alkaloid compositions
[0321] The numerical entries in Table 2 are the "added" ingredients and are rounded.
[0322] As described herein, due to the presence of citric acid and acetic acid in the composition, it is expected that a small amount of alkaloid salt (in this case, (2S)-1-methyl-2-(6-methylpyridin-3-yl)pyrrolidin-1-ium salt) will be formed, and given the molar excess of (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, it is unlikely that any free citric acid or acetic acid will remain as free acid. Compositions 1-5 in Table 2 each contain about 0.04 moles of total organic acid and about 2.15 moles of (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, giving a molar ratio of free base to organic acid of about 54:1.
[0323] For compositions that use 190 proof alcohol instead of absolute alcohol, there will be a small amount of water in the composition (not added separately) and therefore it is not noted as it is not "added". Any composition containing 190 proof alcohol as an ingredient can be converted to a composition with absolute alcohol and water if desired.
[0324] Compositions 1 and 2 simply represent two recipes to achieve the same end result, and composition 1 uses ≥95% crystalline solid capsaicin and composition 2 uses an ethanol extract of total capsaicin alkaloids (i.e., a liquid capsicum extract purchased from OliveNation). As mentioned above, using liquid capsaicin is more convenient and cost-effective.
[0325] The entries in Table 2 demonstrate how other spice additives (shogaols, piperine, and shogaols in these examples) can be used in place of capsaicin or capsaicinoids by adjusting the amount of the substituted spice additive based on its relative pungency (in SHU) to capsaicin. As previously mentioned, slight changes can be made to the solvent to accommodate differences in solubility of the various spice additives. Compositions 1-5 are expected to produce a similar throat hit to the user based on equal SHU pungency between the compositions, but the individual experience may still be personalized based on the person's physiology and their perception.
[0326] Each exemplary composition in Table 2 contains about 100 mg / mL of (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine. It is important to note that these exemplary compositions can be adjusted so that the target w / v of (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine in the composition is about 1 mg / mL to about 1000 mg / mL. Target w / v includes, but is not limited to, 1000 mg / mL, 750 mg / mL, 500 mg / mL, 250 mg / mL, and 100 mg / mL (as shown in Table 2). One advantage of producing concentrates (especially even super concentrates with 1000 mg / mL total w / v substituted pyridine compounds) is reduced transportation costs to manufacturers, compounders, and retailers. A third-party compound manufacturer or end user takes any of these “concentrates” (e.g., 1000 mg / mL, 750 mg / mL, 500 mg / mL, 250 mg / mL, or 100 mg / mL) and dilutes it with PG, VG, or a mixture of PG and VG to have a concentration of <100 mg / mL. w / v target value of substituted pyridine compound, for example, 1 mg / mL, 3 mg / mL, 6 mg / mL, 9 mg / mL, 12 mg / mL, 15 mg / mL, 18 mg / mL, 21 mg / mL, 24 mg / mL, 27 mg / mL, 30 mg / mL, 33 mg / mL, 36 mg / mL, 39 mg / mL, 42 mg / mL, 45 mg / mL, 48 mg / mL, 51 mg / mL, 54 mg / mL, 57 mg / mL, 60 mg / mL, 63 mg / mL, 66 mg / mL, 69 mg / mL, 72 mg / mL, 75 mg / mL, 78 mg / mL, 81 mg / mL, 84 mg / mL, 87 mg / mL, 90 mg / mL, 93 mg / mL, 96 mg / mL or 99 mg / mL.
[0327] Method for preparing vaporizable alkaloid composition
[0328] The vaporizable alkaloid compositions in Tables 1 and 2 can be prepared by directly mixing the ingredients shown in the table in a laboratory container with magnetic or overhead stirring or in a food industry mixer, and then heating if necessary to obtain complete solubility and clarity. In a preferred embodiment, a premix is prepared first and then combined.
[0329] In various embodiments, the first premix, denoted as premix A, comprises propylene glycol, a chemical sensory stimulant such as a spice additive, an organic acid, and 190 proof alcohol. In some examples, two or more organic acids may be present in premix A, and / or PG may be substituted with or included in VG.
[0330] In various embodiments, the second premix, denoted as premix B, comprises the desired substituted pyridine compound of formula (I) dissolved in a compatible solvent, such as vegetable glycerin, propylene glycol, a 50 / 50 (v / v) blend of vegetable glycerin and propylene glycol, and / or ethanol. As described above, in order to obtain highly concentrated compositions, such as those having >20 wt% of the substituted pyridine compound and finished with >100 mg / mL of the substituted pyridine compound, other solvents, such as ethanol, may be required.
[0331] In certain examples, premix A is then combined with premix B and the resulting mixture, if cloudy, is heated at about 190° F. for about 1 hour, or until the mixture is completely clear. After cooling, the mixture will remain clear as it appears that the composition is thermodynamically stable.
[0332] Table 3 lists non-limiting examples of premix A.
[0333] Table 3: Example of Premix A
[0334] Table 4 lists non-limiting examples of premix B.
[0335] Table 4: Examples of Premix B
[0336] In a non-limiting example of combining premixes to produce a final vaporizable alkaloid composition having a target value of 100 mg / mL (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, premix A1 and premix B1 are combined in the weight percentages listed in Table 5, and the resulting mixture is heated at 190°F for approximately 1 hour.
[0337] Table 5: Evaporable alkaloid composition with 100 mg / mL alkaloid target Ingredients (weight %) Final concentration Premix A1 1.54 Premix B1 98.46 total 100.00% by weight
[0338] One way to obtain a final composition with >100 mg / mL alkaloid is to prepare a more concentrated form of premix B, as shown in Table 4, where the alkaloid increases from premix B1 to B4. Depending on the nature and desired concentration of the substituted pyridine compound of formula (I) used in premix B, solubility may become an issue. In these cases, as embodied by the examples in Table 4, when the substituted pyridine compound of formula (I) is (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, the vegetable glycerin in premix B is at least partially replaced by another solvent, such as ethanol.
[0339] The above strategy of using premix A and premix B, wherein the substituted pyridine compound of formula (I) is (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, can reliably achieve (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine levels in the final concentrated vaporizable alkaloid composition of about 225 mg / mL to about 250 mg / mL w / v. To achieve (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine levels in the final composition exceeding about 250 mg / mL w / v, it is necessary to change the solvent of premix B from using only vegetable glycerin to a mixed solvent containing at least some ethanol.
[0340] How to use
[0341] 1. Quitting smoking by inhaling a vaporizable alkaloid composition
[0342] The vaporizable alkaloid composition or dilution thereof according to the present disclosure is intended to be dispensed from an electronic device (eg, an electronic cigarette) in the form of a vapor that a user can inhale like a traditional tobacco product (eg, a cigarette).
[0343] As stated above, one object of the present disclosure is to provide a vaporizable alkaloid composition and progressive dilutions thereof to smokers participating in a smoking cessation program.
[0344] In various embodiments, the method of quitting smoking comprises administering to an individual who wishes to quit smoking a series of vaporizable alkaloid compositions within a determined quitting time period, wherein each vaporizable alkaloid composition in the series comprises at least one substituted pyridine compound or a salt or mixed salt thereof having formula (I):
[0345]
[0346] Where R 1 , R 2 , R 3 and R 4 are independently selected from H, alkyl, cycloalkyl and alkenyl, provided that R 1 , R 2 , R 3 and R 4 It can’t all be H;
[0347] wherein a series of vaporizable alkaloid compositions each comprises a decreasing (w / v) amount of said substituted pyridine compound or a salt or mixed salt thereof;
[0348] wherein an individual who wishes to quit smoking prepares the compositions in the series in descending order of the amount (w / v) of the substituted pyridine compound or its salt or mixed salts; and
[0349] Individuals who wish to quit smoking use each of the compositions by vaporizing and inhaling each composition from an electronic device over a determined quitting time period.
[0350] In various embodiments, the individual desiring to quit smoking is a tobacco smoker who wants to quit smoking.
[0351] In various embodiments, the length of the determined abstinence period may be days, weeks, months, or years, preferably months to a year in length.
[0352] In various embodiments, the abstinence period is part of a abstinence program, the abstinence program further comprising dispensing a series of vaporizable alkaloid compositions during the determined abstinence period.
[0353] In various embodiments, the period of time during which abstinence is determined is divided into successive periods of shorter duration, wherein during each of the shorter periods, the individual desiring abstinence receives and uses a different vaporizable alkaloid composition in place of smoking tobacco. In a preferred embodiment, during each of the successive periods of shorter duration, the individual desiring abstinence receives a vaporizable alkaloid composition having a gradually decreasing amount of alkaloid in (w / v) units.
[0354] In various embodiments, the series of vaporizable alkaloid compositions comprises individual compositions as listed in Table 6. This exemplary series of e-liquids can be administered during a 25-week abstinence program. The table shows that individuals receive new e-liquid compositions with reduced amounts of substituted pyridine compounds each week of the abstinence program. At the end of the program, individuals who wish to abstain will smoke vaporizable alkaloid compositions that do not contain alkaloids.
[0355] Table 6: A range of vaporizable alkaloid compositions for use in smoking cessation programs Plan Week E-cigarette liquid <![CDATA[(mg / mL) alkaloid 1 > 1 P1 <![CDATA[100 2 ]]> 2 P2 95 3 P3 90 4 P4 85 5 P5 80 6 P6 75 7 P7 70 8 P8 65 9 P9 60 10 P10 55 11 P11 50 12 P12 45 13 P13 40 14 P14 35 15 P15 30 16 P16 24 17 P17 21 18 P18 18 19 P19 15 20 P20 12 21 P21 9 22 P22 6 23 P23 3 24 P24 1 25 P25 0
[0356] Note 1: The alkaloid in the composition P1-P25 includes any substituted pyridine compound of formula (I) or its salt or its mixed salt. In a preferred example, the alkaloid in the composition P1-P25 includes (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine or its salt or its mixed salt. In a more preferred example, the composition P1-P25 consists of the composition 1 (or 2) in Table 2 and its dilution.
[0357] Note 2: For plans using a composition containing (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, P1 can be any of the compositions exemplified in Table 2 (each with a target value of 100 mg / mL (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine), preferably composition 1 (or 2). For compositions P2 to P25, as described above, P1 is diluted accordingly with VG and / or PG, flavoring is added as needed, and adjusted according to personal preference.
[0358] In various embodiments, individuals participating in the smoking cessation program will be contacted with their program manager regularly (e.g., weekly) for personal consultation and receive new and further diluted e-cigarette liquids. In these regular inspections, individual compliance with the program can be assessed and adjusted accordingly. Some changes to the program may be to keep individuals at a certain alkaloid w / v level for more than a week, or to change or adjust flavorings. Other changes can be made to a series of suction compositions, such as changing between spice additives, or adding more or less spice additives to adjust the throat hit felt by individuals of the composition provided by the suction. In some examples, a liquid composition is provided to an individual, and the individual places the composition into a reservoir of his / her own refillable electronic device (e.g., a refillable electronic cigarette). In other examples, a disposable (enclosed) device is provided to an individual, which is pre-filled with a specific composition.
[0359] In various embodiments, an individual who has reached the end of the program will smoke only flavored solvents that do not contain alkaloids. At this point, it is expected that the individual will not smoke traditional tobacco products at all and may choose to stop smoking electronic cigarettes altogether.
[0360] In various embodiments, a method of vaping comprises vaporizing and inhaling a composition according to the present disclosure from a disposable (closed) or refillable (open) electronic device. In certain embodiments, the electronic device comprises an electronic cigarette.
[0361] 2. Alkaloid dispensing bag for oral use
[0362] In various embodiments, forms of vaporizable alkaloid compositions according to the present disclosure also find use in manufacturers of "alkaloid dispensing bags". The oral bag includes a relatively small (e.g., 0.5 inch x 0.75 inch) saliva permeable fabric material shell in which a powder is sealed, which can release the alkaloid active material into the individual's oral cavity when the bag is placed under the individual's tongue or in the oral cavity. The alkaloid dispensing bag according to the present disclosure is configured to release the alkaloid of formula (I), or in an alternative embodiment, release the alkaloid of formula (II) over time. In some embodiments, the release of alkaloids from the alkaloid dispensing bag into the individual's oral cavity can be characterized as "timed release".
[0363] In various embodiments, the alkaloid dispensing bag comprises a saliva permeable nonwoven fabric and a powdered alkaloid composition sealed therein. In some examples, the powdered alkaloid composition sealed in the bag comprises an evaporable alkaloid composition according to the present disclosure adsorbed onto a carrier or a carrier mixture so that it presents a physical form of a powder or granules. In other embodiments, the powdered alkaloid composition in the alkaloid dispensing bag comprises a substituted pyridine compound of formula (I) or (II), a solvent and a carrier, wherein the mixture of alkaloid and solvent is adsorbed on the carrier.
[0364] 2a. General Embodiment of Alkaloid Dispensing Bag
[0365] In a general embodiment, an alkaloid dispensing bag suitable for releasing an alkaloid therefrom into the oral cavity of a subject comprises:
[0366] A saliva-permeable nonwoven fabric defining an outer shell containing an alkaloid composition therein, the alkaloid composition comprising:
[0367] At least one substituted pyridine compound of formula (I) or a salt or mixed salt thereof:
[0368] (I), where R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl, provided that if R 5 is CH3, then R 1 , R 2 , R 3 and R 4 cannot all be H; and
[0369] The carrier, wherein the alkaloid dispensing bag is completely free of (R) or (S) nicotine.
[0370] In various embodiments, the alkaloid composition is a mixture of a substituted pyridine compound of formula (I) and a carrier in a solid or oily physical form.
[0371] In various embodiments, the alkaloid composition further comprises a solvent, so that the alkaloid composition can be adsorbed onto the carrier to form a powdered or granular composition that can be filled into the shell. In some examples, the solvent is selected from the group consisting of propylene glycol, vegetable glycerin, water, ethanol, and mixtures thereof.
[0372] In various embodiments, the carrier comprises microcrystalline cellulose.
[0373] In various embodiments, the substituted pyridine compound of formula (I) includes (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine.
[0374] In an alternative general embodiment, an alkaloid dispensing bag suitable for releasing an alkaloid therefrom into the oral cavity of a subject comprises:
[0375] A saliva-permeable nonwoven fabric defining an outer shell containing an alkaloid composition therein, the alkaloid composition comprising:
[0376] At least one substituted pyridine compound of formula (II) or a salt or mixed salt thereof:
[0377]
[0378] Where R 1 , R 2 , R 3 , R 4 , R 10 , R 11 and R 12 is independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl; and n is an integer from 1 to 10; and
[0379] The carrier, wherein the alkaloid dispensing bag is completely free of (R) or (S) nicotine.
[0380] In various embodiments, the alkaloid composition is a mixture of a substituted pyridine compound of formula (II) and a carrier in a solid or oily physical form.
[0381] In various embodiments, the alkaloid composition further comprises a solvent, so that the alkaloid composition can be adsorbed onto the carrier to form a powdered or granular composition that can be filled into the shell. In some examples, the solvent is selected from the group consisting of propylene glycol, vegetable glycerin, water, ethanol, and mixtures thereof.
[0382] In various embodiments, the carrier comprises microcrystalline cellulose.
[0383] In various embodiments, the substituted pyridine compound of formula (II) includes 3-[N-methyl-N-(3-aminopropyl)]aminomethylpyridine.
[0384] In various embodiments, an alkaloid dispensing bag suitable for releasing an alkaloid therefrom into the oral cavity of a subject comprises:
[0385] A saliva-permeable nonwoven fabric defining an outer shell containing an alkaloid composition therein, the alkaloid composition comprising a vaporizable alkaloid composition adsorbed on a carrier, the vaporizable alkaloid composition comprising:
[0386] at least one substituted pyridine compound of formula (I) or a salt or mixed salt thereof;
[0387] (I), where R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl, provided that if R 5 is CH3, then R 1 , R 2 , R 3 and R 4 Cannot be all H;
[0388] at least one chemosensory stimulant;
[0389] at least one solvent; and,
[0390] Optionally, at least one flavoring agent, wherein the alkaloid dispensing bag is completely free of (R) or (S) nicotine.
[0391] In certain instances, the vaporizable alkaloid composition selected according to the present disclosure is adsorbed onto a carrier such as microcrystalline cellulose, so that the resulting material for the bag is in the physical form of a powder or granules.
[0392] Details of chemesensory stimulants such as spice additives, solvents and optional flavoring agents can be found above in the general description of the "Volatilizable alkaloid composition".
[0393] 2b. Saliva-permeable fabric for bags
[0394] The bag material used herein is selected based on its insolubility in water and its permeability to water and saliva. The size of the material should make the filled bag suitable for prolonged sublingual or oral placement. Subjectively, the alkaloid dispensing bag is constructed for a comfortable mouth feel, including the size of the filled and sealed bag and the texture of the bag fabric.
[0395] The bag material used herein can be made of any number of various water-insoluble nonwoven materials, referred to as "fabrics". Nonwoven fabrics have multiple uses and are well known to those skilled in the art of textiles. Nonwovens are described very comprehensively in "Nonwoven Fabrics: Raw Materials, Manufacture, Applications, Characteristics, Testing Processes" (Editors W. Albrecht, H. Fuchs and W. Kittelmann, Wiley-VCH Verlag GmbH & Co. Kga A Weinheim, 2003). Such materials can be prepared by forming a web of continuous filaments and / or staple fibers and optionally bonding these fibers at fiber-to-fiber contact points to provide a fabric with desired properties. The term "bonded nonwoven fabric" is used to include nonwoven fabrics in which the majority of the fiber-to-fiber bonding is achieved by thermal fusion of adjacent fibers, or by adhesive bonding achieved by adding an adhesive to the web to "bond" the fibers together, or by other bonding achieved by making the fibers sticky using a liquid or gas adhesive (usually in combination with heat). Chemical bonding can be achieved by using an adhesive or latex powder dispersed between the fibers in the web and then activated by heat, ultraviolet or infrared radiation or other suitable activation methods. Thermally bonded and chemically bonded carded fiber webs are described in U.S. Pat. No. 6,689,242 to Bodaghi, the subject matter of which is incorporated herein. Thermally bonded and / or chemically bonded nonwoven materials can be used as bag materials herein. Powder bonding is a dry process in which short fibers are first carded to form a fiber web, which is then treated with a powdered thermoplastic adhesive or latex material and passed through a series of ovens and calendar rolls to produce a nonwoven fabric.
[0396] Nonwoven fabrics can also include fibers called "bicomponent fibers", such as "sheath / core bicomponent fibers", which are fibers with an outer sheath region or layer, and whose melting point is lower than the inner core region, so that efficient and controllable thermal bonding can be achieved by melting only the outer layer of each fiber. In other words, the outer surface of the bicomponent fiber can be made to have a lower melting point than the fiber core. For example, adhesive bicomponent fibers (wherein one component has adhesive properties under bonding conditions) are widely used to provide integrity for fiber webs used as absorbents in personal care products or filtration products. In addition, multicomponent fibers are also known and commercially incorporated into nonwovens. Examples of such multicomponent fibers are described in U.S. Patent No. 5,382,400 (Pike et al.) and U.S. Patent No. 5,866,488 of Terada et al., and are incorporated herein in their entirety.
[0397] During fiber bonding, the web can be simultaneously mechanically compressed to achieve the desired bonding, weight, and thickness, a process known as "thermocompression bonding." Thermocompression bonding can be achieved by using heated embossing rolls and heated flat calender rolls in combination with heat treatment machines (e.g., hot air circulation type, hot ventilation type, infrared heater type, or vertical hot air blowing type) for heat compression. Mechanical compression can be used to set the loft or thickness of fabrics with similar basis weights. Generally, increasing basis weight or mass per square area increases thickness, and increasing bonding and compression decreases loft.
[0398] Nonwoven webs can be formed by a variety of processes, such as meltblowing, spunbonding or spinning, open toe, wet-laid, air-laid, combing and high-pressure hydraulic entanglement. The basis weight of nonwoven webs is usually expressed in ounces (osy) or grams per square meter (gsm) of material per square yard, and the fiber diameter is usually expressed in microns, and for staple fibers, it is expressed in "denier". Denier is defined as the number of grams per 9000 meters of fiber length. For fibers with a circular cross-section, denier can be calculated as the fiber diameter in microns squared multiplied by the density in grams / cc, and then multiplied by 0.00707. Lower denier means that the fiber is finer, and higher denier means that the fiber is thicker or heavier. "Average fiber denier" is the sum of the lay denier numbers of each fiber divided by the number of fibers. Denier distribution or "average fiber denier" refers to the distribution of fiber diameters around a specific value. As used herein, the term "bulk density" refers to the weight of a unit volume of material, usually expressed as a unit volume mass (e.g., grams / cubic centimeter). Nonwovens can be produced from fibers having a single average diameter or denier, or two or more average diameter fibers can be used together. For example, two or more distributions of fiber deniers can be combined into a single web (e.g., 2 1 / 2 denier and 4 denier fibers are combed together). The individual fiber webs can then be laminated together. For example, a single nonwoven can contain 2.5, 4, 6 and 15 denier fibers, which means that it is composed of four individual denier fibers (four individual fiber average diameters).
[0399] "Spunbond fibers" refer to filaments formed by extruding molten thermoplastic material, such as described in U.S. Pat. No. 4,340,563 to Appel; U.S. Pat. No. 3,692,618 to Dorschner; U.S. Pat. No. 3,802,817 to Matsuki; U.S. Pat. No. 3,338,992 and U.S. Pat. No. 3,341,394 to Kinney; U.S. Pat. No. 3,502,763 to Hartman; U.S. Pat. No. 3,542,615 to Dobo; and U.S. Pat. No. 5,382,400 to Pike, the entire contents of which are incorporated herein by reference. Spunbond fibers are generally not tacky when deposited onto a collecting surface. Spunbond fibers are generally continuous and have an average diameter of about 7 microns to about 60 microns, most commonly about 15 to 25 microns.
[0400] "Meltblowing" refers to the process of extruding molten thermoplastic material through a plurality of fine, usually circular die capillaries as molten threads or filaments to form converging high-speed, usually hot gas / air streams, causing the filaments of molten thermoplastic material to attenuate to reduce their diameter, ultimately possibly to microfiber diameter. Thereafter, the meltblown fibers are carried by the high-speed gas stream and deposited on a collecting surface to form a randomly dispersed fibrous web. For example, the process is disclosed in U.S. Pat. No. 3,849,241 (Butin et al.). Meltblown fibers are microfibers, which may be continuous or discontinuous, are generally less than 10 microns in average diameter, and are generally tacky when deposited on a collecting surface.
[0401] "Air laying" is a well-known process by which a fibrous nonwoven layer can be formed. In the air laying process, small fiber bundles having a typical length of about 3 to about 52 millimeters are separated and entrained in an air supply, usually with the aid of a vacuum, and deposited on a forming screen. The randomly deposited fibers are then bonded to one another using, for example, hot air to activate an adhesive component or a latex adhesive. The air laying process is taught, for example, in U.S. Patent Nos. 4,640,810 to Laursen and 5,885,516 to Christensen.
[0402] Preferred fibers incorporated into the bag fabric used herein can be single fibers, double fibers (e.g., sheath / core) or multicomponent fibers made of the following materials: polyolefins such as polypropylene, polyethylene; various polyesters such as polyethylene terephthalate-PET, polybutylene terephthalate-PBT or polytrimethylene terephthalate-PTT, polycarbonate or polybutyrate and tile, etc.; viscose rayon; various polyamides such as nylon; polyacrylates; and modified acrylic resins and mixtures of these types of polymers. In various preferred examples, viscose is used as the saliva-permeable nonwoven bag fabric of the alkaloid dispensing bag herein.
[0403] The filling and sealing method for bags containing nonwoven fabrics is disclosed in U.S. Patent Application Publication US2023 / 0211907, which was disclosed and transferred to Swedish Match North Europe AB on July 6, 2023, and is incorporated herein by reference. In various embodiments, the alkaloid distribution bag herein comprises a filling weight of about 100 mg to about 500 mg, preferably about 200 mg to about 400 mg of an alkaloid composition (dry powder or granules). When the bag no longer fits comfortably under the tongue or in the buccal cavity, the upper limit is reached. Since the weight of a small piece of nonwoven fabric is negligible compared to the weight of a single bag, the filling weight of the alkaloid distribution bag herein is about 100 mg to about 500 mg of dry powder or granular alkaloid composition per bag.
[0404] In various embodiments, the alkaloid dispensing bag has a width (or diameter) of about 0.12 inches to about 0.50 inches and a height of about 0.25 to about 0.75 inches. In some examples, the bag may look like a small pillow (e.g., square), or more like a capsule.
[0405] 2c. Powdered filling composition for alkaloid dispensing bag
[0406] In various embodiments, the alkaloid dispensing pouch herein comprises a powdered or granular composition further comprising an alkaloid mixed with a carrier or a liquid alkaloid composition adsorbed onto a carrier. Either approach is intended to produce a dry powdered or granular alkaloid fill material to be sealed within a nonwoven fabric shell.
[0407] The vaporizable alkaloid compositions for use in the alkaloid dispensing bags are described in detail above. Any composition of the substituted pyridine compound of formula (I) or formula (II) in the range of about 1 mg / mL to about 1000 mg / mL may be used. The selected liquid composition is then adsorbed onto a suitable carrier and the resulting powder or granules are used as the filling material for each bag.
[0408] The carriers used herein include, but are not limited to, agar, agarose, albumin, alginate, casein, chitin, chondroitin, dextrin, silk fibroin, rock alginate, galactan, gellan gum, guar gum, scleroglucan, dextran, xylan, pectin, xanthan gum, psyllium, silica gel, fumed silica, magnesium aluminum silicate, clay, bentonite, hectorite, mesoporous silica, cellulose, cellulose acetate, hyaluronic acid, various elastin-like polypeptides, β-cyclodextrin, collagen, gelatin, chitosan, carrageenan, polylactic acid, polyglycolic acid, poly(lactic acid) Acid-glycolic acid) (PLGA), poly (2-hydroxyethyl methacrylate), poly (2-hydroxypropyl methacrylate), poly (acrylic acid), carboxymethyl cellulose, carboxyethyl cellulose, hydroxyethyl cellulose, hydrophobically modified hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose, microcrystalline cellulose, nitrocellulose, polyvinyl alcohol, polyvinyl pyrrolidone, polyvinyl methacrylate, carboxyvinyl polymer, polyvinyl acetate, polyvinyl copolymer, various starches, modified starches and combinations thereof. See SMFijul-Kabir et al., "Cellulose-based hydrogel materials: chemistry, properties and their prospective applications", Prog. Biomater., 7, 153-174 (2018).
[0409] The carrier can be selected based on absorptive capacity, and secondarily on taste. In the case where the carrier does not dissolve at all in the saliva present in the mouth, taste will not be a factor, and any insoluble carrier is unlikely to pass between the fibers of the nonwoven material. In other examples, the carrier may be soluble and will pass through the porous bag fabric along with the alkaloid composition. In a preferred embodiment, the carrier comprises microcrystalline cellulose.
[0410] Tables 7, 8, and 9 list general embodiments of alkaloid compositions that can be used as fill materials for the alkaloid dispensing pouches of the present disclosure.
[0411] Table 7: Filling composition of alkaloid dispensing bag: dry blend Ingredients (weight %) weight% Substituted pyridine compounds of formula (I) or formula (II) 0.1 wt% to 99.9 wt% Fillers (such as microcrystalline cellulose) 0.1 wt% to 99.9 wt% total 100.00% by weight
[0412] Table 8: Filling composition of alkaloid dispensing bag: liquid absorption
[0413] Table 9: Filling composition of alkaloid dispensing bag: liquid absorption Ingredients (weight %) weight% Vaporizable alkaloid compositions (1 mg / mL to 1000 mg / mL w / v alkaloids) 0.1 wt% to 15 wt% Fillers (such as microcrystalline cellulose) 85 wt% to 99.9 wt% total 100.00% by weight
[0414] The physical form of each filling composition shown in Table 7, Table 8 or Table 9 is dry powder or granules. The resulting material is filled into a non-woven bag at a filling level of about 100 mg to about 500 mg of the dry powdered or granulated alkaloid composition per bag, and then sealed to prepare individual alkaloid dispensing bags for oral use.
[0415] In the detailed description, references to "various embodiments," "one embodiment," "an embodiment," "an exemplary embodiment," etc. indicate that the described embodiments may include certain features, structures, or characteristics, but not every embodiment necessarily includes the certain features, structures, or characteristics. Furthermore, these phrases do not necessarily refer to the same embodiment. Furthermore, when a particular feature, structure, or characteristic is described in conjunction with an embodiment, whether or not it is explicitly described, it is considered within the knowledge of those skilled in the art to affect that feature, structure, or characteristic in relation to other embodiments. After reading the specification, it will be clear to those skilled in the relevant art how to implement the present disclosure in alternative embodiments.
[0416] The steps described in any method or process description may be performed in any order and are not necessarily limited to the order presented. In addition, any reference to the singular includes plural embodiments, and any reference to more than one component or step may include singular embodiments or steps. In addition, any reference to attachment, fixing, connection, coupling or the like may include permanent (e.g., integral), removable, temporary, partial, complete and / or any other possible attachment methods. Any components may be connected to each other by friction, snaps, sleeves, brackets, clips, or other devices now known in the art or subsequently developed. In addition, any reference to contactless (or similar phrases) may also include reduced contact or minimal contact.
[0417] Advantages, other benefits, and solutions to problems have been described herein with respect to specific embodiments. However, these benefits, advantages, solutions to problems, and any elements that may cause any benefit, advantage, or solution to occur or become more apparent are not to be construed as key, essential, or basic features or elements of the present disclosure. Therefore, the scope of the present disclosure is limited only by the appended claims, in which, unless expressly stated, a singular element does not mean "one and only one", but rather "one or more". In addition, when a phrase similar to "at least one of A, B, and C" or "at least one of A, B, or C" is used in a claim or specification, the phrase should be interpreted as: in one embodiment there may be only A, in one embodiment there may be only B, in one embodiment there may be only C, or in one embodiment there may be any combination of A, B, and C; for example, A and B, A and C, B and C, or A and B and C.
[0418] All structural, chemical and functional equivalents known to those of ordinary skill in the art to the elements in the various embodiments described above are expressly incorporated herein by reference and are included in the claims. In addition, the claims do not necessarily require that the instrument or the parts of the instrument or the method of using the instrument solve every problem to be solved by the present disclosure. In addition, no element, component or method step in the present disclosure is intended to be disclosed to the public, regardless of whether the element, component or method step is explicitly stated in the claims. Unless the phrase "means" is used to expressly state, no claim element can invoke Section 112(f) of Title 35 of the United States Code. The terms "include", "comprising" or any other variant thereof as used herein are intended to cover non-exclusive inclusions, for example, a chemical, chemical composition, process, method, article or device containing a series of elements does not only include these elements, but may also include other elements that are not explicitly listed or inherent to the chemical, chemical composition, process, method, article or device.
Claims
1. A vaporizable alkaloid composition comprising: At least one substituted pyridine compound of formula (I) or a salt or mixed salt thereof; Where R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from alkyl, H, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl, provided that if R 5 CH 3 , then R 1 , R 2 , R 3 and R 4 Cannot be all H; at least one chemosensory stimulant; at least one solvent; and Optionally, at least one flavoring agent, in, The vaporizable alkaloid composition is completely free of (R) or (S) nicotine.
2. The vaporizable alkaloid composition according to claim 1, in, R 5 Yes CH 3 , and R 1 , R 2 , R 3 and R 4 At least one of them is not H.
3. The vaporizable alkaloid composition of claim 1, wherein R 5 Yes-(CH 2 )n-NR 6 R 7 , in, n is an integer from 1 to 10, and R 6 and R 7 are independently selected from: H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl and substituted alkenyl, or R 6 and R 7 Together with the nitrogen atom to which it is bonded, it forms a 3-8 membered optionally substituted heterocyclic ring.
4. The vaporizable alkaloid composition according to claim 1, in, R 5 is H, and R 1 , R 2 , R 3 and R 4 At least one of them is -(CH 2 )n-NR 6 R 7 , wherein n is an integer from 1 to 10, and R 6 and R 7 is independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl and substituted alkenyl, or R 6 and R 7 Together with the nitrogen atom to which they are bound, they form a 3-8 membered optionally substituted heterocyclic ring.
5. The vaporizable alkaloid composition according to claim 1, in, The substituted pyridine compound or its salt or its mixed salt is selected from: (R) or (S)-3-(pyrrolidin-2-yl)pyridine, (R) or (S)-2-methyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-4-methyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-3-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2,6-dimethyl-3-(1-methylpyrrolidin-2-yl)pyridine (R) or (S) -2,4-dimethyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S) -2,3-dimethyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S) -2,4-dimethyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S) -2,5-dimethyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S) -3,4-dimethyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S) -1-(2- (R) or (S) -1-(3-aminopropyl)-2-(3-pyridyl)pyrrolidine, (R) or (S) -1-(4-aminobutyl)-2-(3-pyridyl)pyrrolidine, (R) or (S) -1-(5-aminopentyl)-2-(3-pyridyl)pyrrolidine, (R) or (S) -1-(2-dimethylaminoethyl)-2-(3-pyridyl)pyrrolidine, (R) or (S) -1-(3-dimethylaminopropyl)-2-(3-pyridyl)pyrrolidine, (R) or (S) - 1-(4-dimethylaminobutyl)-2-(3-pyridyl)pyrrolidine, (R) or (S)-3-(2-(6-methylpyridin-3-yl)pyrrolidin-1-yl)propionitrile, (R) or (S)-4-(2-(6-methylpyridin-3-yl)pyrrolidin-1-yl)butyronitrile, (R) or (S)-1-(3-aminopropyl)-2-(6-methyl-3-pyridyl)pyrrolidine, (R) or (S)-1-[3-(N,N-dimethylamino)propyl]-2-(6-methyl-3-pyridyl)pyrrolidine, (R) or (S)-1-(N,N-diethyl-3-aminopropyl-2-(3-pyridyl)pyrrolidine, (R) or (S)-3-(1-(2-(pyrrolidin-1-yl)ethyl)pyrrolidin-2-yl)pyridine, (R) or (S)-3-(1-(2-(piperidin-1-yl)ethyl)pyrrolidin-2-yl)pyridine, (R) or (S)-4-(2-(2-(pyridin-3-yl)pyrrolidone) (R) or (S)-3-(1-(3-(pyrrolidin-1-yl)propyl)pyrrolidin-2-yl)pyridine, (R) or (S)-3-(1-(3-(piperidin-1-yl)propyl)pyrrolidin-2-yl)pyridine and (R) or (S)-4-(3-(2-(pyridin-3-yl)pyrrolidin-1-yl)propyl)morpholine.
6. The vaporizable alkaloid composition according to claim 1, in, The substituted pyridine compound or its salt or its mixed salt is (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine.
7. The vaporizable alkaloid composition according to claim 1, in, The chemical sensory stimulant is selected from the following group: olive oil stimulating aldehyde, 4-hydroxy-2-nonenal, 4-oxo-2-nonenal, allicin, allyl isothiocyanate, ion channel agonists, polygoni aldehyde, cinnamaldehyde, trans-p-methoxycinnamaldehyde, methyl syringate, 2-chlorobenzylidenemalononitrile, 1-chloroacetophenone, ethyl bromoacetate, 4-hydroxyhexenal, toluene diisocyanate, p-benzoquinone, methyl p-hydroxybenzoate, flufenamic acid, niflumic acid, mefenamic acid, diclofenac, hydroxy-α-benzene, Caprylol, 6-gingerol, linalool, carvacrol, eugenol, thymol, vanillin, methyl eugenol, 2,6-dimethylphenol, 2,5-dimethylphenol, 3,4-dimethylphenol, 2,6-diisopropylphenol, caffeine, farnesylthiosalicylic acid, 4-allylanisole, curcumin, niacin, camphor, avanafil, anandamide, baicalein, baicalin, wogonin, norwogonin, melaleucalyptus A, β-sitosterol and mixtures thereof.
8. The vaporizable alkaloid composition according to claim 1, in, The at least one substituted pyridine compound of formula (I) or its salt or mixed salt thereof is composed of a mixture of the following substances: (S)-2-methyl-3-(1-methylpyrrolidin-2-yl)pyridine free base and (2S)-1-methyl-2-(6-methylpyridin-3-yl)pyrrolidin-1-ium citrate / acetate mixed salt.
9. The vaporizable alkaloid composition of claim 1, wherein the chemesy stimulus is a spice additive exhibiting a pungency of about 1,000 to about 20,000,000 Scoville Heat Units (SHU).
10. The vaporizable alkaloid composition of claim 9, wherein the spice additive is selected from the group consisting of capsaicin, dihydrocapsaicin, norcapsaicin, nordihydrocapsaicin, homocapsaicin, homodihydrocapsaicin, gingerol, piperine, shogaol, isopiperine, piperine, isopiperine, 2-piperidin, piperamide (4,5-dihydropiperine), piperonamide, 4-piperidin, piperine, piperidine, piperine, piperonine, piperine, piperadine (6,7-dihydropiperidin), 5-samantoidine, 6-pseudopiperidin, 7-trisomaline, and mixtures thereof.
11. The vaporizable alkaloid composition according to claim 9, in, The spice additive is a mixture of capsaicin or capsaicinoids.
12. The vaporizable alkaloid composition of claim 1, wherein the solvent is selected from the group consisting of propylene glycol, water, ethanol, glycerol, and mixtures thereof.
13. The vaporizable alkaloid composition of claim 1, further comprising an organic acid selected from the group consisting of formic acid, acetic acid, trifluoroacetic acid, aspartic acid, butyric acid, butyric acid, 2-methylbutyric acid, 3-methylbutyric acid, benzoic acid, caprylic acid, citric acid, crotonic acid, ethylenediaminetetraacetic acid, fumaric acid, gluconic acid, glutamic acid, glyceric acid, glycolic acid, lactic acid, lauric acid, levulinic acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, oxalic acid, phenylacetic acid, phthalic acid, picric acid, propionic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, tartronic acid, valeric acid, and mixtures thereof.
14. The vaporizable alkaloid composition according to claim 13, in, The organic acid is selected from the group consisting of citric acid, acetic acid, benzoic acid, tartaric acid, lactic acid, salicylic acid, malic acid, levulinic acid and mixtures thereof.
15. The vaporizable alkaloid composition of claim 13, in, The molar ratio of total substituted pyridine compounds to total organic acid is from about 25:1 to about 75:
1.
16. A vaporizable alkaloid composition comprising: From about 1% to about 80% by weight of a substituted pyridine compound of formula (I) or a salt or mixed salt thereof: Where R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl, provided that if R 5 CH 3 , then R 1 , R 2 , R 3 and R 4 Cannot be all H; from about 0.05 wt % to about 1.5 wt % total of at least one organic acid; from about 0.0001% to about 0.50% by weight of a spice additive having a pungency of from about 1,000 to about 20,000,000 Scottville Heat Units (SHU); and Residual solvent, in, The weight percentages are based on the total weight of the vaporizable alkaloid composition; and The molar ratio of the molar number of the substituted pyridine compound to the total molar number of the organic acid is about 25:1 to about 75:
1.
17. The vaporizable alkaloid composition of claim 16, in, The substituted pyridine compound is (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine.
18. The vaporizable composition of claim 17, in, The molar ratio of the mole number of (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine to the total mole number of the organic acid is about 50:
1.
19. The vaporizable alkaloid composition of claim 17, in, The (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine (w / v) concentration in the vaporizable alkaloid composition is about 1 mg / mL to about 1,000 mg / mL.
20. The vaporizable alkaloid composition of claim 17, in, The (w / v) concentration of (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine in the vaporizable alkaloid composition is about 100 mg / mL.
21. The vaporizable alkaloid composition of claim 16, in, The at least one organic acid consists of a mixture of citric acid and acetic acid.
22. The vaporizable alkaloid composition of claim 16, in, The spice additive comprises capsaicin.
23. The vaporizable alkaloid composition of claim 16, wherein the solvent is selected from the group consisting of propylene glycol, glycerol, ethanol, and mixtures thereof.
24. A method for producing a vaporizable alkaloid composition, the method include: preparing a first premix comprising at least one organic acid and a chemosensory stimulant dissolved in a suitable solvent or solvent mixture; A second premix is prepared comprising at least one substituted pyridine compound having the structure of formula (I) dissolved in a suitable solvent or solvent mixture: or its salt or mixed salt thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl, provided that if R 5 Yes CH 3 , then R 1 , R 2 , R 3 and R 4 Not all H; combining the first premix and the second premix; and The resulting mixture is optionally heated until the resulting mixture becomes optically clear, thereby producing a vaporizable alkaloid composition.
25. The method of claim 24, in, The first premix includes a mixture of capsaicin or capsaicinoids, acetic acid and citric acid dissolved in a mixture of propylene glycol and ethanol, and the second premix includes (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine dissolved in glycerol.
26. A method for promoting smoking cessation in an individual who wishes to quit smoking, the method include: During the determined smoking cessation period, the individual is administered a series of vaporizable alkaloid compositions for inhalation by the individual via vaporization, each of the series of vaporizable alkaloid compositions comprising at least one substituted pyridine compound having formula (I) or a salt or mixed salt thereof: Where R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl, provided that if R 5 CH 3 , then R 1 , R 2 , R 3 and R 4 Cannot be all H; wherein a series of vaporizable alkaloid compositions each comprises a decreasing (w / v) amount of said substituted pyridine compound or a salt or mixed salt thereof; and wherein the individual inhales by steam inhaling each composition in a series of compositions starting from a composition using the highest content (w / v) of the substituted pyridine compound or its salt or mixed salts and ending with a determined abstinence period starting from a composition using the lowest content (w / v) of the substituted pyridine compound or its salt or mixed salts, such that at the end of the determined abstinence period, the individual quits smoking.
27. The method of claim 26, in, Each vaporizable alkaloid composition in the series of vaporizable alkaloid compositions comprises (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine or a salt or mixed salts thereof.
28. The method of claim 27, in, The vaporizable alkaloid composition in the series of vaporizable alkaloid compositions having the highest level (w / v) of the substituted pyridine compound or salt or mixed salts thereof comprises about 100 mg / mL of (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine.
29. The method of claim 27, in, The vaporizable alkaloid composition in the series of vaporizable alkaloid compositions having the lowest level (w / v) of the substituted pyridine compound or salt or mixed salts thereof comprises no more than about 1 mg / mL of (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine.
30. The method of claim 26, in, The determined abstinence period is part of a smoking cessation program, the smoking cessation program further comprising dispensing a series of vaporizable alkaloid compositions to an individual who wishes to quit smoking during the determined abstinence period.
31. An alkaloid dispensing bag adapted to release an alkaloid therefrom into the oral cavity of an individual, the alkaloid dispensing bag comprising: A saliva-permeable nonwoven fabric defining an outer shell containing an alkaloid composition filled therein, the alkaloid composition comprising: At least one substituted pyridine compound of formula (I) or a salt or mixed salt thereof: Where R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl, provided that if R 5 CH 3 , then R 1 , R 2 , R 3 and R 4 cannot all be H; and carrier, The alkaloid dispensing bag is completely free of (R) or (S) nicotine.
32. The alkaloid dispensing bag according to claim 31, in, The alkaloid composition comprises a mixture of the substituted pyridine compound of formula (I) and the carrier.
33. The alkaloid dispensing bag according to claim 31, in, The carrier includes microcrystalline cellulose.
34. The alkaloid dispensing bag according to claim 31, in, The alkaloid composition further comprises a solvent, and the alkaloid composition consists of a liquid composition adsorbed onto the carrier.
35. The alkaloid dispensing bag according to claim 34, in, The alkaloid composition further comprises a chemosensory stimulant.
36. An alkaloid dispensing bag adapted to release an alkaloid therefrom into the oral cavity of an individual, the alkaloid dispensing bag comprising a saliva permeable nonwoven fabric defining an outer shell containing an alkaloid composition filled therein, the alkaloid composition comprising the vaporizable alkaloid composition of claim 1 adsorbed on a carrier.
37. The alkaloid dispensing bag according to claim 36, in, The vaporizable alkaloid composition comprises (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, citric acid and acetic acid.
38. The alkaloid dispensing bag according to claim 36, in, The carrier includes microcrystalline cellulose.
39. The alkaloid dispensing bag according to claim 36, in, The chemical sensory stimulant includes capsaicin or a mixture of capsaicinoids.
40. The alkaloid dispensing bag of claim 36, in, The solvent is selected from propylene glycol, water, ethanol, glycerol and mixtures thereof.
